{"entity":{"id":"2018","kind":"year","name":"2018 in oncology","aka":["2018"],"tldr":"Everything OnCo dates to 2018: 629 entries, 171 papers, 165 papers listed on people's pages, 113 landmarks and 65 trials reported. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"629 dated entries in OnCo fall in 2018: 171 papers, 165 papers listed on people's pages, 113 landmarks, 65 trials reported, 55 approvals, 26 regulatory events, 13 companies founded, 10 technologies, 3 journals founded, 3 laws and regulations, 3 guideline changes and 2 financing rounds.\n\nOf those, 24 to the day, 5 to the month and 600 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2017","2019"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2018,"events":[{"group":"approval","date":"2018","precision":"year","title":"131I-MIBG (iobenguane I-131) therapy approved in US","note":"Iobenguane scan-positive unresectable, locally advanced or metastatic phaeochromocytoma or paraganglioma in patients 12 and older (Azedra, high-specific-activity form; discontinued...","from":"i131-mibg","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Abiraterone acetate approved in US","note":"High-risk mHSPC (LATITUDE)","from":"abiraterone","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Afatinib approved in US","note":"Uncommon EGFR mutations (S768I, L861Q, G719X)","from":"afatinib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Alectinib approved in England (NICE)","note":"Untreated ALK-positive advanced non-small-cell lung cancer. TA536, published 8 August 2018, within its marketing authorisation subject to the commercial arrangement (ALEX).","from":"alectinib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Anlotinib approved in China","note":"Advanced NSCLC after at least two lines of systemic therapy (ALTER 0303)","from":"anlotinib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Apalutamide approved in US","note":"Non-metastatic CRPC (SPARTAN)","from":"apalutamide","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Arsenic trioxide approved in US","note":"Newly diagnosed low-risk APL with tretinoin","from":"arsenic-trioxide","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase) approved in US","note":"ALL in patients 1 month-21 years (calaspargase pegol)","from":"asparaginase","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Atezolizumab approved in England (NICE)","note":"Locally advanced or metastatic non-small-cell lung cancer after chemotherapy. TA520, published 16 May 2018, stopped at 2 years of uninterrupted treatment or earlier on progression...","from":"atezolizumab","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Bevacizumab approved in US","note":"First-line stage III-IV ovarian cancer after surgery","from":"bevacizumab","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Binimetinib approved in US","note":"BRAF V600E/K melanoma with encorafenib","from":"binimetinib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"BRACAnalysis CDx approved in US","note":"Olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer","from":"bracanalysis-cdx","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Brentuximab vedotin approved in US","note":"First-line stage III/IV Hodgkin lymphoma with AVD","from":"brentuximab-vedotin","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Brigatinib approved in EU","note":"ALK-positive NSCLC","from":"brigatinib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Burosumab approved in EU","note":"X-linked hypophosphataemia; FGF23-related hypophosphataemia in tumour-induced osteomalacia (phosphaturic mesenchymal tumours not curatively resectable or localisable).","from":"burosumab","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Cemiplimab approved in US","note":"Advanced cutaneous squamous cell carcinoma","from":"cemiplimab","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Ceritinib approved in England (NICE)","note":"Untreated ALK-positive advanced non-small-cell lung cancer. TA500, published 24 January 2018, with the discount agreed in the patient access scheme (ASCEND-4).","from":"ceritinib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"clonoSEQ approved in US","note":"MRD in bone marrow, B-cell acute lymphoblastic leukaemia and multiple myeloma (De Novo)","from":"clonoseq","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Dacomitinib approved in US","note":"First-line metastatic NSCLC with EGFR exon 19 del or L858R","from":"dacomitinib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Dasatinib approved in US","note":"Paediatric Ph+ ALL with chemotherapy","from":"dasatinib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Durvalumab approved in US","note":"Unresectable stage III NSCLC after chemoradiation","from":"durvalumab","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Duvelisib approved in US","note":"Relapsed/refractory CLL/SLL after ≥2 prior therapies; FL (withdrawn 2021)","from":"duvelisib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Elotuzumab approved in US","note":"With pomalidomide-dexamethasone after ≥2 therapies","from":"elotuzumab","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Emapalumab approved in US","note":"Primary haemophagocytic lymphohistiocytosis, refractory, recurrent or progressive, or intolerant of conventional therapy","from":"emapalumab","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Encorafenib approved in EU","note":"BRAF V600E-mutant metastatic colorectal cancer, with cetuximab. Braftovi marketing authorisation issued 19 September 2018; the EMA product page lists metastatic colorectal cancer w...","from":"encorafenib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Encorafenib approved in US","note":"BRAF V600 melanoma with binimetinib","from":"encorafenib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Enzalutamide approved in US","note":"Non-metastatic CRPC","from":"enzalutamide","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Fostamatinib approved in US","note":"Chronic immune thrombocytopenia in adults with insufficient response to a previous treatment","from":"fostamatinib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Fruquintinib approved in China","note":"Refractory mCRC (FRESCO)","from":"fruquintinib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Gilteritinib approved in US","note":"Relapsed or refractory FLT3-mutated AML","from":"gilteritinib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Glasdegib approved in US","note":"Newly diagnosed AML in adults ≥75 or unfit for intensive chemotherapy, with low-dose cytarabine","from":"glasdegib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Ivosidenib approved in US","note":"Relapsed/refractory IDH1-mutated AML","from":"ivosidenib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Larotrectinib approved in US","note":"Solid tumours with NTRK gene fusion without known acquired resistance mutation, metastatic or unresectable, adults and children","from":"larotrectinib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Lenvatinib approved in US","note":"First-line unresectable HCC","from":"lenvatinib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Lorlatinib approved in US","note":"ALK+ NSCLC after prior ALK TKI","from":"lorlatinib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Lutetium-177 dotatate approved in US","note":"SSTR+ GEP-NETs","from":"lutathera","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Mecapegfilgrastim approved in CN","note":"Prevention of chemotherapy-induced neutropenia in non-myeloid cancers","from":"mecapegfilgrastim","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Mogamulizumab approved in EU","note":"MF/SS after ≥1 systemic therapy","from":"mogamulizumab","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Mogamulizumab approved in US","note":"Relapsed/refractory mycosis fungoides or Sézary syndrome after ≥1 systemic therapy","from":"mogamulizumab","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Moxetumomab pasudotox approved in US","note":"Relapsed/refractory hairy cell leukaemia after ≥2 systemic therapies including a purine analogue. Withdrawn from market 2023","from":"moxetumomab-pasudotox","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Olaparib approved in US","note":"gBRCA HER2- metastatic breast cancer","from":"olaparib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Osimertinib approved in US","note":"First-line EGFR-mutant NSCLC","from":"osimertinib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Pegfilgrastim approved in US","note":"First biosimilars (Fulphila, Udenyca); further biosimilars 2019 onwards","from":"pegfilgrastim","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Pembrolizumab approved in England (NICE)","note":"Untreated PD-L1-positive metastatic non-small-cell lung cancer with a tumour proportion score of 50 percent or more and no EGFR or ALK alteration.","from":"pembrolizumab","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"ProFound AI (iCAD) approved in US","note":"510(k) clearance: AI detection for digital breast tomosynthesis (first for 3D mammography)","from":"icad-profound-ai","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Pyrotinib approved in China","note":"HER2+ advanced breast cancer with capecitabine","from":"pyrotinib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Ravulizumab approved in US","note":"Paroxysmal nocturnal haemoglobinuria. Later extended to atypical haemolytic uraemic syndrome and generalised myasthenia gravis","from":"ravulizumab","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Rucaparib approved in US","note":"Maintenance in recurrent ovarian cancer after platinum response (now BRCA-mutated only)","from":"rucaparib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Sintilimab approved in China","note":"Relapsed or refractory classical Hodgkin lymphoma after two or more lines","from":"sintilimab","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Tagraxofusp approved in US","note":"Blastic plasmacytoid dendritic cell neoplasm, adults and children ≥2","from":"tagraxofusp","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Talazoparib approved in US","note":"gBRCA HER2- locally advanced/metastatic breast cancer","from":"talazoparib","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Tisagenlecleucel approved in US","note":"Relapsed/refractory DLBCL","from":"tisagenlecleucel","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Toripalimab approved in China","note":"Melanoma (first of many indications)","from":"toripalimab","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Transpara approved in US","note":"510(k) clearance, 2D mammography","from":"transpara","refs":[]},{"group":"approval","date":"2018","precision":"year","title":"Venetoclax approved in US","note":"AML with azacitidine/decitabine/LDAC in unfit patients","from":"venetoclax","refs":[]},{"group":"company","date":"2018","precision":"year","title":"Canopy founded","note":"New York, NY","from":"canopy","refs":[]},{"group":"company","date":"2018","precision":"year","title":"Curesponse founded","note":"Rehovot","from":"curesponse","refs":[]},{"group":"company","date":"2018","precision":"year","title":"Halda Therapeutics founded","note":"New Haven, CT","from":"halda-therapeutics","refs":[]},{"group":"company","date":"2018","precision":"year","title":"Immunai founded","note":"New York, NY","from":"immunai","refs":[]},{"group":"company","date":"2018","precision":"year","title":"ImmunoACT founded","note":"Mumbai","from":"immunoact","refs":[]},{"group":"company","date":"2018","precision":"year","title":"Jeito Capital founded","note":"Paris","from":"jeito-capital","refs":[]},{"group":"company","date":"2018","precision":"year","title":"Kumquat Biosciences founded","note":"San Diego, CA","from":"kumquat-biosciences","refs":[]},{"group":"company","date":"2018","precision":"year","title":"Nuvation Bio founded","note":"New York, NY","from":"nuvation-bio","refs":[]},{"group":"company","date":"2018","precision":"year","title":"SunHo Biopharmaceutical founded","note":"Nanjing","from":"sunho-biopharmaceutical","refs":[]},{"group":"company","date":"2018","precision":"year","title":"TAE Life Sciences founded","note":"Irvine, CA","from":"tae-life-sciences","refs":[]},{"group":"company","date":"2018","precision":"year","title":"Tallac Therapeutics founded","note":"Burlingame, CA","from":"tallac-therapeutics","refs":[]},{"group":"company","date":"2018","precision":"year","title":"Vara founded","note":"Berlin","from":"vara","refs":[]},{"group":"company","date":"2018","precision":"year","title":"Wigen Biomedicine Technology (Shanghai) founded","note":"Shanghai","from":"wigen-biomedicine-technology-shanghai","refs":[]},{"group":"funding","date":"2018","precision":"year","title":"Radformation: Seed","note":"$2m. Led by Brooklyn Bridge Ventures with angel investors","from":"radformation","refs":[]},{"group":"funding","date":"2018","precision":"year","title":"TAE Life Sciences: Series A","note":"$40m. Led by ARTIS Ventures; company launched as a majority-owned subsidiary of fusion company TAE Technologies","from":"tae-life-sciences","refs":[]},{"group":"history","date":"2018","precision":"year","title":"Adjuvant mFOLFIRINOX (PRODIGE 24)","note":"Pancreatic ductal adenocarcinoma. Median OS 54 months after resection.","from":"pancreatic","refs":["prodige-24"]},{"group":"history","date":"2018","precision":"year","title":"Aggarwal: 17 percent of men on potent hormone therapy have neuroendocrine features at biopsy","note":"Neuroendocrine and small-cell prostate cancer","from":"prostate-nepc","refs":["castration-resistance"]},{"group":"history","date":"2018","precision":"year","title":"AJCC 8th edition gives HPV-positive oropharynx cancer its own staging","note":"Head and neck squamous cell carcinoma","from":"head-and-neck","refs":["hpv-p16","tnm-staging"]},{"group":"history","date":"2018","precision":"year","title":"ALTA-1L: brigatinib beats crizotinib first line","note":"ALK-positive non-small-cell lung cancer","from":"alk-positive-nsclc","refs":["alta-1l","brigatinib","ross-camidge"]},{"group":"history","date":"2018","precision":"year","title":"American Cancer Society lowers the screening start age to 45","note":"Early-onset colorectal cancer (under 50)","from":"early-onset-colorectal","refs":["colorectal-screening"]},{"group":"history","date":"2018","precision":"year","title":"AREN0533: lung radiotherapy omitted for rapid complete responders","note":"Wilms tumour (nephroblastoma)","from":"wilms-tumor","refs":["imrt-igrt"]},{"group":"history","date":"2018","precision":"year","title":"Arsenic trioxide approved for first-line standard-risk APL in the United States","note":"Acute promyelocytic leukaemia","from":"apl","refs":["arsenic-trioxide"]},{"group":"history","date":"2018","precision":"year","title":"ASCO and NCCN recommend germline testing for every patient with pancreatic cancer","note":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","from":"brca-palb2-pdac","refs":["germline-testing","gbrca-mutation"]},{"group":"history","date":"2018","precision":"year","title":"Blinatumomab approved for MRD-positive ALL","note":"Acute lymphoblastic leukaemia. First approval based on an MRD endpoint (BLAST).","from":"all-leukemia","refs":["blinatumomab","mrd-negative-cr"]},{"group":"history","date":"2018","precision":"year","title":"Cemiplimab: first systemic approval for cSCC","note":"Cutaneous squamous cell carcinoma. EMPOWER-CSCC-1 (NEJM 2018).","from":"cutaneous-scc","refs":["cemiplimab"]},{"group":"history","date":"2018","precision":"year","title":"CheckMate 204: immunotherapy doublet works in the brain","note":"Advanced melanoma (unresectable stage III and stage IV)","from":"advanced-melanoma","refs":["checkmate-204"]},{"group":"history","date":"2018","precision":"year","title":"CheckMate 204: nivolumab plus ipilimumab active in melanoma brain metastases","note":"Brain metastases (secondary brain tumours)","from":"secondary-brain-tumours","refs":["nivolumab","ipilimumab"]},{"group":"history","date":"2018","precision":"year","title":"Checkpoint inhibitors in cutaneous angiosarcoma","note":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma).","from":"vascular-tumours","refs":["checkpoint-inhibitor"]},{"group":"history","date":"2018","precision":"year","title":"Co-mutations, and the testing guideline that followed","note":"Non-small-cell lung cancer. STK11 and KEAP1 are tied to poor immunotherapy outcomes in KRAS-mutant disease; the College of American Pathologists, the International Association for...","from":"nsclc","refs":["paper-kras-nsclc-cancer-discov-2018","paper-arbour-kras-co-mutation-outcomes-ccr-2018","paper-lindeman-lung-molecular-testing-guideline-jto-2018","stk11"]},{"group":"history","date":"2018","precision":"year","title":"COLUMBUS: encorafenib-binimetinib approved","note":"BRAF V600-mutant melanoma","from":"braf-v600-melanoma","refs":["columbus","encorafenib","binimetinib"]},{"group":"history","date":"2018","precision":"year","title":"Dabrafenib plus trametinib approved (ROAR)","note":"Anaplastic thyroid cancer. The first drug approval for this cancer.","from":"anaplastic-thyroid-cancer","refs":["dabrafenib","trametinib"]},{"group":"history","date":"2018","precision":"year","title":"Dabrafenib-trametinib approved for BRAF V600E anaplastic thyroid cancer (ROAR); larotrectinib tumour-agnostic","note":"Thyroid cancer","from":"thyroid","refs":["roar-atc","dabrafenib-trametinib","ntrk"]},{"group":"history","date":"2018","precision":"year","title":"Dasatinib approved for children with Ph-positive ALL after CA180-372","note":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)","from":"all-paediatric-ph-positive","refs":["dasatinib"]},{"group":"history","date":"2018","precision":"year","title":"ECHELON-1: brentuximab vedotin with AVD beats ABVD","note":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","from":"advanced-stage-classical-hodgkin-lymphoma","refs":["echelon-1","brentuximab-vedotin"]},{"group":"history","date":"2018","precision":"year","title":"ECHELON-1: BV-AVD approved frontline; radiotherapy omission trials (RAPID, HD16/17) report","note":"Hodgkin lymphoma","from":"hodgkin-lymphoma","refs":["echelon-1","pet-adapted-therapy"]},{"group":"history","date":"2018","precision":"year","title":"ECHELON-2 and mogamulizumab","note":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma). Brentuximab-CHP improves OS over CHOP; mogamulizumab approved for MF/Sézary (MAVORIC).","from":"peripheral-t-cell-lymphoma","refs":["brentuximab-vedotin","mogamulizumab"]},{"group":"history","date":"2018","precision":"year","title":"ELIANA published: 81 percent remission in 75 heavily pretreated children","note":"Relapsed and refractory acute lymphoblastic leukaemia in children","from":"all-paediatric-relapsed","refs":["paper-eliana-tisagenlecleucel-nejm-2018","eliana"]},{"group":"history","date":"2018","precision":"year","title":"EMBRACA and IMpassion130","note":"Metastatic triple-negative breast cancer","from":"tnbc-metastatic","refs":["embraca","talazoparib","impassion130","atezolizumab"]},{"group":"history","date":"2018","precision":"year","title":"EMPOWER-CSCC-1: cemiplimab is the first approved systemic therapy","note":"Advanced cutaneous squamous cell carcinoma","from":"advanced-cutaneous-scc","refs":["empower-cscc-1","cemiplimab"]},{"group":"history","date":"2018","precision":"year","title":"Encorafenib + binimetinib approved (COLUMBUS); Nobel Prize to Allison and Honjo","note":"Melanoma","from":"melanoma","refs":["columbus","encorafenib","binimetinib"]},{"group":"history","date":"2018","precision":"year","title":"EORTC 90101 CREATE phase 2","note":"Inflammatory myofibroblastic tumour (IMT). Schöffski and colleagues, Lancet Respir Med: high response rate in ALK-positive IMT.","from":"inflammatory-myofibroblastic-tumour","refs":["crizotinib"]},{"group":"history","date":"2018","precision":"year","title":"ESE guideline for aggressive pituitary tumours and carcinomas","note":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma. Temozolomide as first-line chemotherapy.","from":"pituitary-tumours","refs":["temozolomide"]},{"group":"history","date":"2018","precision":"year","title":"ESE/ENSAT guideline sets Ki-67 and resection status as the basis for adjuvant mitotane","note":"Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)","from":"localised-adrenocortical-carcinoma","refs":["mitotane"]},{"group":"history","date":"2018","precision":"year","title":"Euro-EWING 99 R2: busulfan-melphalan benefit in high-risk localised disease","note":"Ewing sarcoma","from":"ewing-sarcoma","refs":["autologous-stem-cell-transplant"]},{"group":"history","date":"2018","precision":"year","title":"EURO-SKI: half of patients stopping treatment stay in remission","note":"Chronic myeloid leukaemia, chronic phase","from":"cml-chronic-phase","refs":["molecular-response"]},{"group":"history","date":"2018","precision":"year","title":"European evidence-based guidelines on pancreatic cystic neoplasms","note":"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors","from":"ipmn-cystic-precursors","refs":["pancreatic-surveillance"]},{"group":"history","date":"2018","precision":"year","title":"Everolimus phase 2 shows disease control in pretreated thymic epithelial tumours; severe immune toxicity of PD-1 antibodies in thymoma reported","note":"Thymoma (WHO types A, AB, B1, B2 and B3)","from":"thymoma","refs":["everolimus","irae"]},{"group":"history","date":"2018","precision":"year","title":"FIGO 2018 staging splits IB by tumour size and adds imaging and nodal status","note":"Early cervical cancer and fertility-sparing surgery","from":"early-cervical-cancer","refs":[]},{"group":"history","date":"2018","precision":"year","title":"First consensus recommendations for diagnosis and treatment (Blood)","note":"Rosai-Dorfman-Destombes disease","from":"rosai-dorfman-disease","refs":[]},{"group":"history","date":"2018","precision":"year","title":"First immunotherapy signal","note":"Triple-negative breast cancer (TNBC). IMpassion130: atezolizumab + nab-paclitaxel improves PFS in PD-L1+ metastatic TNBC (approval later withdrawn).","from":"tnbc","refs":["impassion130","atezolizumab"]},{"group":"history","date":"2018","precision":"year","title":"FLAURA: first-line osimertinib beats gefitinib and erlotinib","note":"EGFR-mutated non-small-cell lung cancer","from":"egfr-mutant-nsclc","refs":["flaura","osimertinib","jean-charles-soria","suresh-ramalingam"]},{"group":"history","date":"2018","precision":"year","title":"GD2 identified as a target on H3 K27M gliomas","note":"Diffuse midline glioma, H3 K27-altered (including DIPG). Mount and Monje (Nature Medicine) show GD2 CAR-T clears tumours in mouse models.","from":"dipg-dmg","refs":["gd2","glioma-car-t"]},{"group":"history","date":"2018","precision":"year","title":"Germline faults in 5.5 percent regardless of family history; CAPS surveillance finds operable cancers","note":"Pancreatic ductal adenocarcinoma. Hu, 3,030 patients. Canto, 354 high-risk individuals over 16 years: 9 of 10 surveillance-detected cancers resectable.","from":"pancreatic","refs":["paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018","paper-canto-caps-long-term-surveillance-gastroenterology-2018","paper-sharma-endpac-model-new-onset-diabetes-gastroenterology-2018","idea-pdac-surveillance-for-every-germline-carrier"]},{"group":"history","date":"2018","precision":"year","title":"Gilteritinib approved for relapsed FLT3-mutated AML after ADMIRAL","note":"FLT3-mutated acute myeloid leukaemia","from":"aml-flt3","refs":["admiral","gilteritinib"]},{"group":"history","date":"2018","precision":"year","title":"GOG-0277 closed early","note":"Uterine sarcoma. Adjuvant chemotherapy for stage I LMS did not improve outcomes; observation is standard.","from":"uterine-sarcoma","refs":["gemcitabine","docetaxel"]},{"group":"history","date":"2018","precision":"year","title":"HERBY: bevacizumab adds nothing to radiotherapy and temozolomide","note":"Paediatric high-grade glioma (excluding diffuse midline glioma). Grill and colleagues (JCO).","from":"paediatric-high-grade-glioma","refs":["bevacizumab-glioma","temozolomide"]},{"group":"history","date":"2018","precision":"year","title":"High-specific-activity 131I-MIBG (Azedra) approved","note":"Pheochromocytoma and paraganglioma (PPGL). FDA, July 2018, for unresectable MIBG-positive PPGL; later discontinued commercially.","from":"pheochromocytoma-paraganglioma","refs":["i131-mibg"]},{"group":"history","date":"2018","precision":"year","title":"High-specific-activity 131I-MIBG (Azedra) approved in the United States","note":"Metastatic pheochromocytoma and paraganglioma","from":"metastatic-ppgl","refs":["i131-mibg"]},{"group":"history","date":"2018","precision":"year","title":"IDEA: 3 months of adjuvant CAPOX suffices for low-risk stage III","note":"Colorectal cancer","from":"colorectal","refs":["capox"]},{"group":"history","date":"2018","precision":"year","title":"IMpower133: atezolizumab plus chemotherapy, the first survival gain in decades","note":"Extensive-stage small-cell lung cancer","from":"extensive-stage-sclc","refs":["impower133","atezolizumab","luis-paz-ares"]},{"group":"history","date":"2018","precision":"year","title":"IMpower133: first survival gain in decades with atezolizumab","note":"Small-cell lung cancer","from":"sclc","refs":["impower133","atezolizumab"]},{"group":"history","date":"2018","precision":"year","title":"iNNOVATE: ibrutinib-rituximab","note":"Waldenström macroglobulinaemia","from":"waldenstrom","refs":["ibrutinib","rituximab"]},{"group":"history","date":"2018","precision":"year","title":"International DICER1 surveillance consensus published","note":"Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)","from":"pleuropulmonary-blastoma","refs":["germline-testing"]},{"group":"history","date":"2018","precision":"year","title":"International Male Breast Cancer Program (EORTC 10085)","note":"Male breast cancer. Cardoso and colleagues (Ann Oncol 2018) characterise 1,483 men treated 1990 to 2010.","from":"male-breast-cancer","refs":[]},{"group":"history","date":"2018","precision":"year","title":"Ivosidenib approved for relapsed IDH1-mutated AML","note":"IDH1- and IDH2-mutated acute myeloid leukaemia","from":"aml-idh","refs":["ivosidenib"]},{"group":"history","date":"2018","precision":"year","title":"Ivosidenib, gilteritinib, and venetoclax combinations","note":"Acute myeloid leukaemia. Ivosidenib (IDH1) and gilteritinib (ADMIRAL) approved; venetoclax + HMA/LDAC gets accelerated approval for unfit AML.","from":"aml","refs":["ivosidenib","gilteritinib","admiral","venetoclax"]},{"group":"history","date":"2018","precision":"year","title":"KATHERINE, TRAIN-2 and KRISTINE","note":"Early HER2-positive breast cancer","from":"her2-positive-early-breast-cancer","refs":["katherine","trastuzumab-emtansine","train-2","kristine"]},{"group":"history","date":"2018","precision":"year","title":"KATHERINE: T-DM1 for residual disease","note":"HER2-positive breast cancer","from":"breast-her2-positive","refs":["katherine"]},{"group":"history","date":"2018","precision":"year","title":"KEYNOTE-054: adjuvant pembrolizumab beats placebo","note":"Stage III melanoma (after surgery)","from":"stage-iii-melanoma","refs":["nct02362594","pembrolizumab"]},{"group":"history","date":"2018","precision":"year","title":"KEYNOTE-189 and KEYNOTE-407: pembrolizumab plus chemotherapy for all PD-L1 levels","note":"PD-L1-high non-small-cell lung cancer without a driver mutation","from":"pdl1-high-nsclc","refs":["keynote-024-189","pembrolizumab","paper-keynote-189-nejm-2018"]},{"group":"history","date":"2018","precision":"year","title":"LACC: minimally invasive radical hysterectomy inferior to open surgery","note":"Early cervical cancer and fertility-sparing surgery","from":"early-cervical-cancer","refs":["lacc"]},{"group":"history","date":"2018","precision":"year","title":"LACC: minimally invasive radical hysterectomy is inferior","note":"Cervical cancer. Practice reverses to open surgery within months.","from":"cervical","refs":["lacc"]},{"group":"history","date":"2018","precision":"year","title":"Larotrectinib approved for NTRK fusion-positive solid tumours, pancreatic cancer included","note":"KRAS wild-type pancreatic ductal adenocarcinoma","from":"kras-wild-type-pdac","refs":["larotrectinib","ntrk"]},{"group":"history","date":"2018","precision":"year","title":"Larotrectinib approved tumour-agnostically, including secretory carcinoma","note":"Salivary gland cancers","from":"salivary-gland","refs":["larotrectinib"]},{"group":"history","date":"2018","precision":"year","title":"Larotrectinib: tumour-agnostic approval for NTRK fusion cancers","note":"NTRK fusion-positive non-small-cell lung cancer","from":"ntrk-fusion-nsclc","refs":["larotrectinib","navigate","tumour-agnostic","alexander-drilon"]},{"group":"history","date":"2018","precision":"year","title":"Leuprorelin with bicalutamide: phase 2 response rate 41.7 percent","note":"Salivary duct carcinoma","from":"salivary-duct-carcinoma","refs":["leuprolide","bicalutamide"]},{"group":"history","date":"2018","precision":"year","title":"Lutathera approved","note":"Neuroendocrine tumours","from":"neuroendocrine","refs":["lutathera"]},{"group":"history","date":"2018","precision":"year","title":"Lutathera approved (NETTER-1): PRRT enters standard care","note":"Neuroendocrine tumours","from":"neuroendocrine","refs":["lutathera","prrt"]},{"group":"history","date":"2018","precision":"year","title":"Lutathera approved for gastroenteropancreatic tumours","note":"Pancreatic neuroendocrine tumours","from":"pancreatic-net","refs":["lutathera","prrt"]},{"group":"history","date":"2018","precision":"year","title":"Lutathera approved in the United States and Europe","note":"Small intestinal neuroendocrine tumours","from":"small-intestinal-net","refs":["lutathera","prrt"]},{"group":"history","date":"2018","precision":"year","title":"MAVORIC: mogamulizumab approved","note":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","from":"cutaneous-t-cell-lymphoma","refs":["mogamulizumab"]},{"group":"history","date":"2018","precision":"year","title":"MIPSS70 adds mutations to risk scoring for transplant decisions","note":"Primary myelofibrosis","from":"primary-myelofibrosis","refs":[]},{"group":"history","date":"2018","precision":"year","title":"Moxetumomab pasudotox approved","note":"Hairy cell leukaemia. First CD22 immunotoxin; withdrawn from the US market in 2023 for commercial reasons.","from":"hairy-cell-leukemia","refs":["moxetumomab-pasudotox"]},{"group":"history","date":"2018","precision":"year","title":"MURANO: two years of venetoclax-rituximab beats chemoimmunotherapy","note":"Relapsed or refractory chronic lymphocytic leukaemia","from":"cll-relapsed","refs":["venetoclax","rituximab"]},{"group":"history","date":"2018","precision":"year","title":"National Cancer Database comparison: worse survival in resected stage I and II disease","note":"Adenosquamous carcinoma of the pancreas","from":"pancreatic-adenosquamous-carcinoma","refs":["whipple"]},{"group":"history","date":"2018","precision":"year","title":"NICE NG85: pancreatic cancer in adults","note":"Pancreatic ductal adenocarcinoma. Pancreatic protocol CT before biliary drainage, PET-CT for localised disease, enzyme replacement for unresectable disease, surveillance criteria f...","from":"pancreatic","refs":["pancreas-protocol-ct","pancreatic-enzyme-replacement","pancreatic-surveillance"]},{"group":"history","date":"2018","precision":"year","title":"Nivolumab plus ipilimumab first line (CheckMate 214)","note":"Clear cell renal cell carcinoma","from":"clear-cell-rcc","refs":["checkmate-214"]},{"group":"history","date":"2018","precision":"year","title":"Nivolumab-ipilimumab first line","note":"Renal cell carcinoma","from":"rcc","refs":[]},{"group":"history","date":"2018","precision":"year","title":"Nivolumab-ipilimumab first line (CheckMate 214); CARMENA questions cytoreductive nephrectomy","note":"Renal cell carcinoma","from":"rcc","refs":["checkmate-214"]},{"group":"history","date":"2018","precision":"year","title":"NRG1 fusions described as a recurrent driver of KRAS wild-type pancreatic cancer","note":"KRAS wild-type pancreatic ductal adenocarcinoma","from":"kras-wild-type-pdac","refs":["gene-fusion","her3"]},{"group":"history","date":"2018","precision":"year","title":"NRG1 fusions in KRAS wild-type disease; germline carriers mostly lack a family history","note":"Pancreatic ductal adenocarcinoma. NRG1 fusions found in every KRAS wild-type tumour of a young-adult series (Heining), later put at about 1% of all pancreatic cancers (Philip 2022)...","from":"pancreatic","refs":["paper-shindo-germline-sporadic-pancreatic-jco-2017","paper-heining-nrg1-fusions-kras-wild-type-pancreatic-cancer-discov-2018","paper-philip-kras-wild-type-pancreatic-ccr-2022","brca-germline"]},{"group":"history","date":"2018","precision":"year","title":"Osimertinib first line (FLAURA); first tumour-agnostic approval (larotrectinib)","note":"Non-small-cell lung cancer","from":"nsclc","refs":["osimertinib","ntrk"]},{"group":"history","date":"2018","precision":"year","title":"PARP inhibitors in BRCA breast cancer","note":"Triple-negative breast cancer (TNBC). OlympiAD and EMBRACA lead to olaparib and talazoparib approvals.","from":"tnbc","refs":["olaparib","talazoparib"]},{"group":"history","date":"2018","precision":"year","title":"Pembrolizumab approved","note":"Merkel cell carcinoma","from":"merkel-cell-carcinoma","refs":["pembrolizumab"]},{"group":"history","date":"2018","precision":"year","title":"Pembrolizumab approved for PD-L1-positive cervical cancer","note":"Vaginal cancer. Extended in practice to HPV-associated vaginal cancer.","from":"vaginal","refs":["pembrolizumab"]},{"group":"history","date":"2018","precision":"year","title":"Pembrolizumab approved for relapsed or refractory disease after KEYNOTE-170","note":"Primary mediastinal (thymic) large B-cell lymphoma","from":"primary-mediastinal-b-cell-lymphoma","refs":["pembrolizumab","keynote-170"]},{"group":"history","date":"2018","precision":"year","title":"Pembrolizumab in thymic carcinoma: activity with severe irAEs (Giaccone, Lancet Oncol)","note":"Thymoma and thymic carcinoma","from":"thymic-epithelial","refs":["pembrolizumab"]},{"group":"history","date":"2018","precision":"year","title":"Pembrolizumab phase 2 in thymic carcinoma: 22.5 percent response, 15 percent severe immune toxicity","note":"Thymic carcinoma","from":"thymic-carcinoma","refs":["pembrolizumab","irae"]},{"group":"history","date":"2018","precision":"year","title":"Photodynamic therapy loses its place at the front","note":"Skin cancer (all types). Five-year results of the 601-patient Dutch trial: tumour-free survival 80.5 per cent with imiquimod, 70.0 with fluorouracil and 62.7 with methyl aminolevul...","from":"skin-cancer","refs":["mal-pdt-imiquimod-fluorouracil-superficial-bcc"]},{"group":"history","date":"2018","precision":"year","title":"PORTEC-3: chemoradiation plus chemotherapy for high-risk disease","note":"Endometrial cancer","from":"endometrial","refs":["portec-3"]},{"group":"history","date":"2018","precision":"year","title":"PORTEC-3: chemoradiation plus chemotherapy improves survival in high-risk disease","note":"p53-abnormal endometrial cancer, including uterine serous carcinoma","from":"endometrial-p53-abnormal","refs":["portec-3"]},{"group":"history","date":"2018","precision":"year","title":"PRECISION: MRI before biopsy","note":"Prostate cancer","from":"prostate","refs":["precision-mri","mp-mri"]},{"group":"history","date":"2018","precision":"year","title":"PRECISION: MRI-targeted biopsy beats systematic biopsy","note":"Localised prostate cancer, very low and low risk","from":"prostate-low-risk","refs":["precision-mri"]},{"group":"history","date":"2018","precision":"year","title":"PRODIGE 24: six months of modified FOLFIRINOX after surgery sets the adjuvant standard","note":"Resectable pancreatic ductal adenocarcinoma","from":"resectable-pdac","refs":["prodige-24","folfirinox","thierry-conroy"]},{"group":"history","date":"2018","precision":"year","title":"Randomised phase 2: trastuzumab with carboplatin-paclitaxel improves survival in HER2-positive serous carcinoma","note":"p53-abnormal endometrial cancer, including uterine serous carcinoma","from":"endometrial-p53-abnormal","refs":["trastuzumab","her2"]},{"group":"history","date":"2018","precision":"year","title":"REFLECT: lenvatinib non-inferior first line; CELESTIAL: cabozantinib second line","note":"Hepatocellular carcinoma","from":"hcc","refs":["reflect","celestial"]},{"group":"history","date":"2018","precision":"year","title":"REFLECT: lenvatinib non-inferior to sorafenib; CELESTIAL: cabozantinib in later lines","note":"Advanced hepatocellular carcinoma (BCLC C)","from":"hcc-advanced","refs":["reflect","lenvatinib","celestial","cabozantinib"]},{"group":"history","date":"2018","precision":"year","title":"RELEVANCE: chemo-free R²","note":"Follicular lymphoma. Lenalidomide-rituximab matches chemo-immunotherapy first line.","from":"follicular-lymphoma","refs":["lenalidomide"]},{"group":"history","date":"2018","precision":"year","title":"Retrospective series favour fluoropyrimidine and oxaliplatin regimens over gemcitabine","note":"Pancreatic acinar cell carcinoma","from":"pancreatic-acinar-cell-carcinoma","refs":["folfox","folfirinox"]},{"group":"history","date":"2018","precision":"year","title":"SIOPEL-6: sodium thiosulfate halves cisplatin hearing loss (NEJM)","note":"Hepatoblastoma. FDA approval of sodium thiosulfate (Pedmark) 2022.","from":"hepatoblastoma","refs":["sodium-thiosulfate"]},{"group":"history","date":"2018","precision":"year","title":"Sodium thiosulfate protects hearing","note":"Germ cell tumours of childhood and adolescence (extracranial and CNS). SIOPEL 6 (NEJM 2018) and ACCL0431 show reduced cisplatin ototoxicity; FDA approval 2022.","from":"paediatric-germ-cell-tumours","refs":["sodium-thiosulfate"]},{"group":"history","date":"2018","precision":"year","title":"SOLO-1 and OVHIPEC-1","note":"Ovarian cancer. Two years of first-line olaparib maintenance (PFS HR 0.30) and HIPEC at interval surgery (OS +12 months) both reported.","from":"ovarian","refs":["solo-1","ovhipec-1"]},{"group":"history","date":"2018","precision":"year","title":"SOLO-1: olaparib maintenance transforms BRCA-mutant first-line outcomes","note":"High-grade serous ovarian cancer","from":"high-grade-serous-ovarian-cancer","refs":["solo-1"]},{"group":"history","date":"2018","precision":"year","title":"SOLO-1: olaparib maintenance, progression hazard ratio 0.30 in BRCA-mutant first-line disease","note":"Platinum-sensitive ovarian cancer","from":"platinum-sensitive-ovarian-cancer","refs":["solo-1"]},{"group":"history","date":"2018","precision":"year","title":"Sorafenib beats placebo (Alliance A091105)","note":"Desmoid tumour. Gounder and colleagues, NEJM.","from":"desmoid-tumour","refs":["sorafenib"]},{"group":"history","date":"2018","precision":"year","title":"SPARTAN and PROSPER: apalutamide and enzalutamide approved for nmCRPC","note":"Non-metastatic castration-resistant prostate cancer","from":"prostate-nmcrpc","refs":["apalutamide","enzalutamide"]},{"group":"history","date":"2018","precision":"year","title":"Tagraxofusp approved","note":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN). First CD123-targeted therapy and first drug approved for BPDCN.","from":"bpdcn","refs":["tagraxofusp"]},{"group":"history","date":"2018","precision":"year","title":"TAILORx: most women can skip chemotherapy","note":"HR-positive / HER2-negative breast cancer","from":"breast-hr-positive","refs":["tailorx"]},{"group":"history","date":"2018","precision":"year","title":"TAILORx: no chemotherapy benefit for intermediate recurrence scores","note":"High-risk early HR-positive breast cancer","from":"hr-positive-early-high-risk","refs":["tailorx","oncotype-dx"]},{"group":"history","date":"2018","precision":"year","title":"The enhancer nobody was looking at, and the long tail","note":"Prostate cancer. Deep whole genomes of 101 metastases find the AR upstream enhancer amplified in 81% of men, invisible to exome panels; reanalysis of 1,013 exomes finds 97 driver g...","from":"prostate","refs":["paper-quigley-structural-variation-mcrpc-cell-2018","paper-armenia-long-tail-oncogenic-drivers-prostate-nat-genet-2018","androgen-receptor"]},{"group":"history","date":"2018","precision":"year","title":"The International Watch and Wait Database reports on 880 rectal cancers","note":"Colorectal cancer. Among people with a complete clinical response after chemoradiotherapy who kept their rectum, local regrowth reached 25.2 percent at two years, almost all in the...","from":"colorectal","refs":["watch-and-wait-rectal-cancer","clinical-complete-response"]},{"group":"history","date":"2018","precision":"year","title":"TNT: germline BRCA, not the HRD score, predicts platinum benefit","note":"Triple-negative breast cancer (TNBC). In 376 advanced patients carboplatin doubled the response rate in germline BRCA carriers while the Myriad HRD score and BRCA1 methylation pred...","from":"tnbc","refs":["paper-tutt-nat-med","paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018","hrd-positive"]},{"group":"history","date":"2018","precision":"year","title":"Treatment-free remission validated","note":"Chronic myeloid leukaemia (CML). EURO-SKI: about half of patients stopping TKI stay in remission.","from":"cml","refs":["mrd"]},{"group":"history","date":"2018","precision":"year","title":"TROG 05.01: chemotherapy adds nothing to postoperative radiotherapy","note":"Cutaneous squamous cell carcinoma. 321 patients randomised; freedom from locoregional relapse at five years 87 against 83 per cent with weekly carboplatin added, hazard ratio 0.84.","from":"cutaneous-scc","refs":["trog-05-01"]},{"group":"history","date":"2018","precision":"year","title":"Two long-running localised trials read out, and the disparity question is reframed","note":"Prostate cancer. SPCG-4 at 29 years: surgery cut prostate cancer death by 45 percent in clinically detected disease and added a mean 2.9 years of life.","from":"prostate","refs":["paper-bill-axelson-spcg-4-29-year-nejm-2018","paper-wilt-pivot-prostatectomy-observation-nejm-2017","paper-dess-black-race-prostate-mortality-jama-oncol-2019","paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018"]},{"group":"history","date":"2018","precision":"year","title":"UICC TNM 8 becomes the UK staging standard for breast cancer","note":"Breast cancer (all types). Used for all breast tumours diagnosed after 1 January 2018. The Royal College of Pathologists reprints it and advises against substituting the American A...","from":"breast-cancer","refs":["tnm-breast-cancer-editions","ajcc-prognostic-stage-breast"]},{"group":"history","date":"2018","precision":"year","title":"Venetoclax and glasdegib combinations gain accelerated approval for unfit AML","note":"Acute myeloid leukaemia in older or unfit patients","from":"aml-older-unfit","refs":["venetoclax","glasdegib"]},{"group":"history","date":"2018","precision":"year","title":"Why microsatellite-stable disease is cold","note":"Colorectal cancer. Mice with all four main colorectal mutations reproduce human microsatellite-stable disease and answer checkpoint blockade only once TGF-beta is inhibited; across...","from":"colorectal","refs":["paper-tauriello-tgfbeta-immune-evasion-colorectal-nature-2018","paper-grasso-immune-evasion-colorectal-cancer-discov-2018","b2m"]},{"group":"journal","date":"2018","precision":"year","title":"Cancer communications founded","note":"American Association for the Advancement of Science (Science Partner Journals)","from":"cancer-communications","refs":[]},{"group":"journal","date":"2018","precision":"year","title":"Cancer reports founded","note":"Wiley","from":"cancer-reports","refs":[]},{"group":"journal","date":"2018","precision":"year","title":"European Urology Oncology founded","note":"Elsevier","from":"european-urology-oncology","refs":[]},{"group":"law","date":"2018","precision":"year","title":"China National Reimbursement Drug List negotiation and volume-based procurement","note":"China, scheme.","from":"china-vbp-nrdl","refs":[]},{"group":"law","date":"2018","precision":"year","title":"Right to Try Act 2018 and state right-to-try laws","note":"United States, statute.","from":"right-to-try","refs":[]},{"group":"law","date":"2018","precision":"year","title":"UK Data Protection Act 2018 and health data law","note":"United Kingdom, statute.","from":"uk-data-protection-act","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"89 Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","note":"Bensch F, van der Veen EL, Lub-de Hooge MN, et al. Nature Medicine.","from":"paper-bensch-nat-med","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers","note":"Chun YS, Pawlik TM, Vauthey JN. Annals of Surgical Oncology.","from":"paper-chun-ajcc-8th-edition-hepatobiliary-aso-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"A common classification framework for neuroendocrine neoplasms (IARC and WHO expert consensus)","note":"Rindi G, Klimstra DS, Abedi-Ardekani B, et al. Modern Pathology.","from":"paper-rindi-common-classification-framework-mod-pathol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"A PET imaging agent for evaluating PARP-1 expression in ovarian cancer","note":"Makvandi M, Pantel A, Schwartz L, et al. Journal of Clinical Investigation.","from":"paper-makvandi-j-clin-invest","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or re...","note":"Zhao WH, Liu J, Wang BY, et al. Journal of hematology & oncology.","from":"paper-zhao-j-hematol-oncol","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","note":"Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, et al. EMBO molecular medicine.","from":"paper-castroviejo-bermejo-embo-mol-med","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Access to pathology and laboratory medicine services: a crucial gap","note":"Wilson ML, Fleming KA, Kuti MA, et al. The Lancet.","from":"paper-wilson-lancet","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE","note":"Alexander BM, Ba S, Berger MS, et al. Clinical Cancer Research.","from":"paper-alexander-clin-cancer-res","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","note":"Zammarchi F, Corbett S, Adams L, et al. Blood.","from":"paper-zammarchi-blood","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess...","note":"Loibl S, O'Shaughnessy J, Untch M, et al. The Lancet Oncology.","from":"paper-brightness-lancet-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Allemani 2018: CONCORD-3, global surveillance of cancer survival 2000 to 2014","note":"Allemani C, Matsuda T, Di Carlo V, et al. The Lancet.","from":"paper-allemani-concord-3-lancet-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Alleviating the access abyss in palliative care and pain relief-an imperative of universal health coverage: the Lancet Commission report","note":"Knaul FM, Farmer PE, Krakauer EL, et al. The Lancet.","from":"paper-knaul-lancet","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","note":"Oxnard GR, Hu Y, Mileham KF, et al. JAMA Oncology.","from":"paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer","note":"Hu C, Hart SN, Polley EC, et al. JAMA.","from":"paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma","note":"Qian ZR, Rubinson DA, Nowak JA, et al. JAMA Oncology.","from":"paper-qian-driver-genes-outcomes-resected-pancreatic-jama-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","note":"Schmid P, Adams S, Rugo HS, et al. New England Journal of Medicine.","from":"paper-impassion130-n-engl-j-med-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Binnewies 2018: understanding the tumour immune microenvironment for effective therapy","note":"Binnewies M, Roberts EW, Kersten K, et al. Nature Medicine.","from":"paper-binnewies-tumor-immune-microenvironment-natmed-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Biodistribution and Dosimetry of 18 F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies","note":"Pandit-Taskar N, Zanzonico P, Staton KD, et al. Journal of Nuclear Medicine.","from":"paper-pandit-taskar-j-nucl-med","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Biology and treatment of Richter syndrome","note":"Rossi D, Spina V, Gaidano G. Blood.","from":"paper-rossi-richter-syndrome-blood-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","note":"Gandara DR, Paul SM, Kowanetz M, et al. Nature Medicine.","from":"paper-gandara-blood-tmb-atezolizumab-nat-med-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Bourgeois-Daigneault 2018: giving the virus before surgery, not after everything else has failed","note":"Bourgeois-Daigneault MC, Roy DG, Aitken AS, et al. Science Translational Medicine.","from":"paper-bourgeois-daigneault-neoadjuvant-ovt-tnbc-scitranslmed-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers","note":"Bray F, Ferlay J, Soerjomataram I, et al. CA: A Cancer Journal for Clinicians.","from":"paper-bray-globocan-2018-cacancer-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer","note":"Camidge DR, Kim HR, Ahn MJ, et al. New England Journal of Medicine.","from":"paper-alta-1l-n-engl-j-med-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial","note":"Solheim TS, Laird BJA, Balstad TR, et al. BMJ supportive & palliative care.","from":"paper-solheim-bmj-support-palliat-care","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","note":"Tutt A, Tovey H, Cheang MCU, et al. Nature Medicine.","from":"paper-tutt-nat-med","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Carboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma","note":"Fader AN, Roque DM, Siegel E, et al. Journal of Clinical Oncology.","from":"paper-fader-trastuzumab-uterine-serous-jco-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program","note":"Cardoso F, Bartlett JMS, Slaets L, et al. Annals of Oncology.","from":"paper-cardoso-ann-oncol","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"CheckMate 205: nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous transplant failure, extended follow-up","note":"Armand P, Engert A, Younes A, et al. Journal of Clinical Oncology.","from":"paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"CheckMate 214: nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma","note":"Motzer RJ, Tannir NM, McDermott DF, et al. New England Journal of Medicine.","from":"paper-checkmate-214-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Chromosomal instability drives metastasis through a cytosolic DNA response","note":"Bakhoum SF, Ngo B, Laughney AM, et al. Nature.","from":"paper-bakhoum-nature","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","note":"Kurtz DM, Scherer F, Jin MC, et al. Journal of Clinical Oncology.","from":"paper-kurtz-j-clin-oncol","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Circulating tumour DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","note":"Annala M, Vandekerkhove G, Khalaf D, et al. Cancer Discovery.","from":"paper-annala-ctdna-resistance-abiraterone-enzalutamide-cancer-discov-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes","note":"Loree JM, Pereira AAL, Lam M, et al. Clinical Cancer Research.","from":"paper-loree-tumour-location-continuum-colorectal-ccr-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Clinical and genomic characterisation of treatment-emergent small-cell neuroendocrine prostate cancer","note":"Aggarwal R, Huang J, Alumkal JJ, et al. Journal of Clinical Oncology.","from":"paper-aggarwal-t-sccpc-jco-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy","note":"Neyaz A, Husain N, Kumari S, et al. Histopathology.","from":"paper-neyaz-pdl1-gallbladder-histopathology-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Clinical sequencing defines the genomic landscape of metastatic colorectal cancer","note":"Yaeger R, Chatila WK, Lipsyc MD, et al. Cancer Cell.","from":"paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"COLUMBUS: encorafenib plus binimetinib versus vemurafenib or encorafenib in BRAF-mutant melanoma","note":"Dummer R, Ascierto PA, Gogas HJ, et al. The Lancet Oncology.","from":"paper-columbus-lancet-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Combined androgen blockade in androgen receptor-positive salivary gland carcinoma","note":"Fushimi C, Tada Y, Takahashi H, et al. Annals of Oncology.","from":"paper-fushimi-androgen-deprivation-salivary-duct-ann-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain","note":"Tawbi HA, Forsyth PA, Algazi A, et al. New England Journal of Medicine.","from":"paper-checkmate-204-n-engl-j-med-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients","note":"Kahles A, Lehmann KV, Toussaint NC, et al. Cancer Cell.","from":"paper-kahles-cancer-cell","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease","note":"Abla O, Jacobsen E, Picarsic J, et al. Blood.","from":"paper-rosai-dorfman-destombes-consensus-recommendations-blood-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Consumption of ultra-processed foods and cancer risk: results from NutriNet-Santé prospective cohort","note":"Fiolet T, Srour B, Sellem L, et al. BMJ.","from":"paper-fiolet-bmj","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"CPX-351 versus 7+3 chemotherapy in older adults with newly diagnosed secondary acute myeloid leukaemia","note":"Lancet JE, Uy GL, Cortes JE, et al. Journal of Clinical Oncology.","from":"paper-cpx-351-study-301-lancet-je-jco-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Org...","note":"Schöffski P, Sufliarsky J, Gelderblom H, et al. The Lancet. Respiratory medicine.","from":"paper-schoffski-lancet-respir-med","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Dabrafenib and trametinib in BRAF V600E-mutant anaplastic thyroid cancer (ROAR)","note":"Subbiah V, Kreitman RJ, Wainberg ZA, et al. Journal of Clinical Oncology.","from":"paper-subbiah-dabrafenib-trametinib-atc-jco-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer","note":"Gilligan AM, Alberts DS, Roe DJ, et al. The American journal of medicine.","from":"paper-gilligan-am-j-med","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","note":"Cohen JD, Li L, Wang Y, et al. Science.","from":"paper-cohen-cancerseek-multi-analyte-blood-test-science-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies","note":"Schultz KAP, Williams GM, Kamihara J, et al. Clinical Cancer Research.","from":"paper-schultz-clin-cancer-res","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","note":"Henricks LM, Lunenburg CATC, de Man FM, et al. The Lancet Oncology.","from":"paper-henricks-lancet-oncol","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory acute myeloid leukaemia","note":"DiNardo CD, Stein EM, de Botton S, et al. New England Journal of Medicine.","from":"paper-ivosidenib-idh1-dinardo-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Duration of adjuvant chemotherapy for stage III colon cancer (the IDEA collaboration)","note":"Grothey A, Sobrero AF, Shields AF, et al. New England Journal of Medicine.","from":"paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma","note":"Connors JM, Jurczak W, Straus DJ, et al. New England Journal of Medicine.","from":"paper-echelon-1-brentuximab-avd-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Random...","note":"Han B, Li K, Wang Q, et al. JAMA Oncology.","from":"paper-alter-0303-jama-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Effect of Aspirin on All-Cause Mortality in the Healthy Elderly","note":"McNeil JJ, Nelson MR, Woods RL, et al. New England Journal of Medicine.","from":"paper-mcneil-n-engl-j-med","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","note":"Arbour KC, Jordan E, Kim HR, et al. Clinical Cancer Research.","from":"paper-arbour-kras-co-mutation-outcomes-ccr-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial","note":"Hanai A, Ishiguro H, Sozu T, et al. JNCI: Journal of the National Cancer Institute.","from":"paper-hanai-j-natl-cancer-inst","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL","note":"Maude SL, Laetsch TW, Buechner J, et al. New England Journal of Medicine.","from":"paper-eliana-tisagenlecleucel-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Emerging functions of the EGFR in cancer","note":"Sigismund S, Avanzato D, Lanzetti L. Molecular oncology.","from":"paper-egfr-glioblastoma-mol-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer","note":"Freites-Martinez A, Shapiro J, Chan D, et al. JAMA dermatology.","from":"paper-freites-martinez-jama-dermatol","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer","note":"Traina TA, Miller K, Yardley DA, et al. Journal of Clinical Oncology.","from":"paper-traina-enzalutamide-ar-tnbc-jco-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"EsPhALL2010: continuous imatinib with chemotherapy in paediatric Philadelphia chromosome-positive ALL","note":"Biondi A, Gandemer V, De Lorenzo P, et al. The Lancet Haematology.","from":"paper-esphall2010-continuous-imatinib-biondi-lancet-haematol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"European evidence-based guidelines on pancreatic cystic neoplasms (2018)","note":"European Study Group on Cystic Tumours of the Pancreas. Gut.","from":"paper-european-evidence-based-guidelines-pancreatic-cystic-neoplasms-gut-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"European Society of Endocrinology and ENSAT clinical practice guidelines on the management of adrenocortical carcinoma in adults","note":"Fassnacht M, Dekkers OM, Else T, et al. European Journal of Endocrinology.","from":"paper-ese-ensat-adrenocortical-carcinoma-guideline-eur-j-endocrinol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","note":"Raverot G, Burman P, McCormack A, et al. European journal of endocrinology.","from":"paper-raverot-eur-j-endocrinol","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update","note":"Oktay K, Harvey BE, Partridge AH, et al. Journal of Clinical Oncology.","from":"paper-oktay-j-clin-oncol","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"FIGO Cancer Report 2018: cancer of the vagina","note":"Adams TS, Cuello MA. International Journal of Gynecology & Obstetrics.","from":"paper-figo-cancer-report-cancer-of-the-vagina-ijgo-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","note":"Horn L, Mansfield AS, Szczęsna A, et al. New England Journal of Medicine.","from":"paper-impower133-n-engl-j-med-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer","note":"Soria JC, Ohe Y, Vansteenkiste J, et al. New England Journal of Medicine.","from":"paper-flaura-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Genetic mechanisms of immune evasion in colorectal cancer","note":"Grasso CS, Giannakis M, Wells DK, et al. Cancer Discovery.","from":"paper-grasso-immune-evasion-colorectal-cancer-discov-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Genome doubling shapes the evolution and prognosis of advanced cancers","note":"Bielski CM, Zehir A, Penson AV, et al. Nature Genetics.","from":"paper-bielski-nat-genet","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","note":"Wardell CP, Fujita M, Yamada T, et al. Journal of Hepatology.","from":"paper-wardell-biliary-drivers-germline-j-hepatol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Genomic hallmarks and structural variation in metastatic prostate cancer","note":"Quigley DA, Dang HX, Zhao SG, et al. Cell.","from":"paper-quigley-structural-variation-mcrpc-cell-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial","note":"Aung KL, Fischer SE, Denroche RE, et al. Clinical Cancer Research.","from":"paper-aung-compass-early-results-ccr-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"GRAALL-2005: randomised hyperfractionated cyclophosphamide in a paediatric-inspired adult ALL protocol","note":"Huguet F, Chevret S, Leguay T, et al. Journal of Clinical Oncology.","from":"paper-graall-2005-huguet-jco-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Heining 2018: NRG1 fusions in KRAS wild-type pancreatic cancer","note":"Heining C, Horak P, Uhrig S, et al. Cancer Discovery.","from":"paper-heining-nrg1-fusions-kras-wild-type-pancreatic-cancer-discov-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer","note":"Jones BA, Varambally S, Arend RC. Molecular Cancer Therapeutics.","from":"paper-ezh2-ovarian-mol-cancer-ther-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Hu 2018: evaluating mismatch repair deficiency in pancreatic adenocarcinoma, challenges and recommendations","note":"Hu ZI, Shia J, Stadler ZK, et al. Clinical Cancer Research.","from":"paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guid...","note":"Wolff AC, Hammond MEH, Allison KH, et al. Journal of Clinical Oncology.","from":"paper-wolff-j-clin-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-act...","note":"Mok TS, Cheng Y, Zhou X, et al. Journal of Clinical Oncology.","from":"paper-archer-1050-os-jco-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome","note":"Pfeiffer A, Thalheimer FB, Hartmann S, et al. EMBO molecular medicine.","from":"paper-pfeiffer-embo-mol-med","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Inherited breast cancer in Nigerian women","note":"Zheng Y, Walsh T, Gulsuner S, et al. Journal of Clinical Oncology.","from":"paper-zheng-nigerian-inherited-breast-cancer-jco-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline","note":"Lyman GH, Greenlee H, Bohlke K, et al. Journal of Clinical Oncology.","from":"paper-lyman-j-clin-oncol","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","note":"Herrera AF, Moskowitz AJ, Bartlett NL, et al. Blood.","from":"paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"International validation of the consensus Immunoscore for the classification of colon cancer","note":"Pages F, Mlecnik B, Marliot F, et al. Lancet.","from":"paper-pages-immunoscore-international-validation-lancet-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Intraductal and ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer","note":"Isaacsson Velho P, Silberstein JL, Markowski MC, et al. The Prostate.","from":"paper-isaacsson-velho-intraductal-germline-dna-repair-prostate-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"IPMNs with co-occurring invasive cancers: neighbours but not always relatives","note":"Felsenstein M, Noe M, Masica DL, et al. Gut.","from":"paper-felsenstein-ipmn-cooccurring-cancer-relatedness-gut-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"KEYNOTE-054 (EORTC 1325): adjuvant pembrolizumab versus placebo in resected stage III melanoma","note":"Eggermont AMM, Blank CU, Mandala M, et al. New England Journal of Medicine.","from":"paper-keynote-054-eggermont-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation","note":"Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. New England Journal of Medicine.","from":"paper-keynote-189-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"LACC: minimally invasive versus open radical hysterectomy for early cervical cancer","note":"Ramirez PT, Frumovitz M, Pareja R, et al. New England Journal of Medicine.","from":"paper-lacc-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Larotrectinib in TRK fusion-positive cancers in adults and children","note":"Drilon A, Laetsch TW, Kummar S, et al. New England Journal of Medicine.","from":"paper-drilon-larotrectinib-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BO...","note":"Lear JT, Migden MR, Lewis KD, et al. Journal of the European Academy of Dermatology and Venereology.","from":"paper-bolt-j-eur-acad-dermatol-venereol-2018-update","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors","note":"Andricovich J, Perkail S, Kai Y, et al. Cancer Cell.","from":"paper-andricovich-kdm6a-squamous-pancreatic-cancer-cell-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"MAVORIC: mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma","note":"Kim YH, Bagot M, Pinter-Brown L, et al. The Lancet Oncology.","from":"paper-mavoric-mogamulizumab-lancet-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes","note":"Sharma A, Kandlakunta H, Nagpal SJS, et al. Gastroenterology.","from":"paper-sharma-endpac-model-new-onset-diabetes-gastroenterology-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Molecular determinants of response to anti-PD-1 and anti-PD-L1 blockade in patients with non-small-cell lung cancer profiled with targeted next-generation seque...","note":"Rizvi H, Sanchez-Vega F, La K, et al. Journal of Clinical Oncology.","from":"paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL","note":"Seymour JF, Kipps TJ, Eichhorst B, et al. New England Journal of Medicine.","from":"paper-murano-venetoclax-rituximab-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a ra...","note":"Hurvitz SA, Martin M, Symmans WF, et al. The Lancet Oncology.","from":"paper-kristine-lancet-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice","note":"Albrengues J, Shields MA, Ng D, et al. Science.","from":"paper-albrengues-science","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden","note":"Hellmann MD, Ciuleanu TE, Pluzanski A, et al. New England Journal of Medicine.","from":"paper-checkmate-227-n-engl-j-med-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Non-epithelial ovarian cancer: ESMO clinical practice guidelines","note":"Ray-Coquard I, Morice P, Lorusso D, et al. Annals of Oncology.","from":"paper-esmo-non-epithelial-ovarian-ray-coquard-ann-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Nuclear-localised androgen receptor splice variant 7 in circulating tumour cells as a predictive biomarker in castration-resistant prostate cancer","note":"Scher HI, Graf RP, Schreiber NA, et al. JAMA Oncology.","from":"paper-scher-nuclear-arv7-taxane-vs-arsi-jama-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"NY-ESO-1 c259 T-cell receptor therapy in synovial sarcoma: prolonged persistence and antitumour activity","note":"D'Angelo SP, Melchiori L, Merchant MS, et al. Cancer Discovery.","from":"paper-dangelo-ny-eso-1-tcr-synovial-sarcoma-cancer-discov-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Optimal surgical treatment in patients with T1b gallbladder cancer: An international multicenter study","note":"Kim HS, Park JW, Kim H, et al. Journal of Hepato-Biliary-Pancreatic Sciences.","from":"paper-kim-t1b-gallbladder-cancer-international-jhbps-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer","note":"Tiriac H, Belleau P, Engle DD, et al. Cancer Discovery.","from":"paper-tiriac-cancer-discov","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-...","note":"Dummer R, Ascierto PA, Gogas HJ, et al. The Lancet Oncology.","from":"paper-columbus-lancet-oncol-2018-update","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","note":"Antonia SJ, Villegas A, Daniel D, et al. New England Journal of Medicine.","from":"paper-pacific-n-engl-j-med-2018-update","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","note":"Cristescu R, Mogg R, Ayers M, et al. Science.","from":"paper-cristescu-science","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","note":"Tetzlaff MT, Messina JL, Stein JE, et al. Annals of Oncology.","from":"paper-tetzlaff-ann-oncol","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1)","note":"Migden MR, Rischin D, Schmults CD, et al. New England Journal of Medicine.","from":"paper-empower-cscc-1-cemiplimab-migden-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project","note":"Tsao MS, Kerr KM, Kockx M, et al. Journal of Thoracic Oncology.","from":"paper-blueprint-phase-2-pd-l1-assays-jto-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Pembrolizumab in patients with thymic carcinoma: a single-arm phase 2 study","note":"Giaccone G, Kim C, Thompson J, et al. The Lancet Oncology.","from":"paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","note":"Paz-Ares L, Luft A, Vicente D, et al. New England Journal of Medicine.","from":"paper-keynote-407-n-engl-j-med-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules","note":"Patel KN, Angell TE, Babiarz J, et al. JAMA surgery.","from":"paper-patel-jama-surg","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastas...","note":"Ishigami H, Fujiwara Y, Fukushima R, et al. Journal of Clinical Oncology.","from":"paper-ishigami-j-clin-oncol","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems","note":"Ghaffarizadeh A, Heiland R, Friedman SH, et al. PLoS computational biology.","from":"paper-ghaffarizadeh-plos-comput-biol","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"PORTEC-3: adjuvant chemoradiotherapy versus radiotherapy alone for high-risk endometrial cancer","note":"de Boer SM, Powell ME, Mileshkin L, et al. The Lancet Oncology.","from":"paper-portec-3-lancet-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology","note":"Mohile SG, Dale W, Somerfield MR, et al. Journal of Clinical Oncology.","from":"paper-mohile-j-clin-oncol","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Precancerous neoplastic cells can move through the pancreatic ductal system","note":"Makohon-Moore AP, Matsukuma K, Zhang M, et al. Nature.","from":"paper-makohon-moore-precursor-cells-ductal-system-nature-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"PRECISION: MRI-targeted or standard biopsy for prostate cancer diagnosis","note":"Kasivisvanathan V, Rannikko AS, Borghi M, et al. New England Journal of Medicine.","from":"paper-precision-mri-targeted-biopsy-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer","note":"Wei D, Heus P, van de Wetering FT, et al. The Cochrane database of systematic reviews.","from":"paper-wei-cochrane-database-syst-rev","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"PRODIGE 24/CCTG PA6: adjuvant modified FOLFIRINOX versus gemcitabine after resection of pancreatic cancer","note":"Conroy T, Hammel P, Hebbar M, et al. New England Journal of Medicine.","from":"paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States","note":"Islami F, Goding Sauer A, Miller KD, et al. CA: A Cancer Journal for Clinicians.","from":"paper-islami-ca-cancer-j-clin","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","note":"Lowery MA, Wong W, Jordan EJ, et al. JNCI: Journal of the National Cancer Institute.","from":"paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer","note":"Szmulewitz RZ, Peer CJ, Ibraheem A, et al. Journal of Clinical Oncology.","from":"paper-szmulewitz-j-clin-oncol","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"PROSPER: enzalutamide in men with non-metastatic castration-resistant prostate cancer","note":"Hussain M, Fizazi K, Saad F, et al. New England Journal of Medicine.","from":"paper-prosper-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","note":"Parker CC, James ND, Brawley CD, et al. The Lancet.","from":"paper-parker-lancet","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","note":"Aguirre AJ, Nowak JA, Camarda ND, et al. Cancer Discovery.","from":"paper-aguirre-real-time-genomic-characterisation-pancreatic-cancer-discov-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"REFLECT: lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma","note":"Kudo M, Finn RS, Qin S, et al. The Lancet.","from":"paper-reflect-lenvatinib-lancet-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"RELEVANCE: rituximab plus lenalidomide in advanced untreated follicular lymphoma","note":"Morschhauser F, Fowler NH, Feugier P, et al. New England Journal of Medicine.","from":"paper-relevance-rituximab-lenalidomide-follicular-lymphoma-morschhauser-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"RESTORE: bipolar androgen therapy after progression on enzalutamide in metastatic castration-resistant prostate cancer","note":"Teply BA, Wang H, Luber B, et al. The Lancet Oncology.","from":"paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic...","note":"Lichtman AH, Lux EA, McQuade R, et al. Journal of pain and symptom management.","from":"paper-lichtman-j-pain-symptom-manage","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","note":"Robey RW, Pluchino KM, Hall MD, et al. Nature Reviews Cancer.","from":"paper-robey-nat-rev-cancer","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Ribas and Wolchok 2018: cancer immunotherapy using checkpoint blockade","note":"Ribas A, Wolchok JD. Science.","from":"paper-ribas-wolchok-checkpoint-blockade-science-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance","note":"Canto MI, Almario JA, Schulick RD, et al. Gastroenterology.","from":"paper-canto-caps-long-term-surveillance-gastroenterology-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Self-collected HPV samples are as accurate as clinician samples and reach women who never attend screening","note":"Arbyn M, Smith SB, Temin S, Sultana F, Castle P. BMJ.","from":"paper-hpv-self-sampling-bmj-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Siegel 2018: Cancer statistics, 2018","note":"Siegel RL, Miller KD, Jemal A. CA: A Cancer Journal for Clinicians.","from":"paper-siegel-cancer-statistics-2018-cacancer-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss","note":"Brock PR, Maibach R, Childs M, et al. New England Journal of Medicine.","from":"paper-brock-n-engl-j-med","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","note":"Casali PG, Abecassis N, Aro HT, et al. Annals of Oncology.","from":"paper-robin-jones-ann-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer","note":"Moore K, Colombo N, Scambia G, et al. New England Journal of Medicine.","from":"paper-solo-1-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Somatic mutant clones colonize the human esophagus with age","note":"Martincorena I, Fowler JC, Wabik A, et al. Science.","from":"paper-martincorena-science","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"SPARTAN: apalutamide for non-metastatic castration-resistant prostate cancer","note":"Smith MR, Saad F, Chowdhury S, et al. New England Journal of Medicine.","from":"paper-spartan-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"SPCG-4: radical prostatectomy or watchful waiting in prostate cancer, 29-year follow-up","note":"Bill-Axelson A, Holmberg L, Garmo H, et al. New England Journal of Medicine.","from":"paper-bill-axelson-spcg-4-29-year-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma","note":"Skoulidis F, Goldberg ME, Greenawalt DM, et al. Cancer Discovery.","from":"paper-kras-nsclc-cancer-discov-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features","note":"Puleo F, Nicolle R, Blum Y, et al. Gastroenterology.","from":"paper-puleo-pancreatic-tumour-microenvironment-subtypes-gastroenterology-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from Gepar...","note":"Loibl S, Weber KE, Timms KM, et al. Annals of Oncology.","from":"paper-loibl-geparsixto-survival-hrd-ann-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"TAILORx: adjuvant chemotherapy guided by the 21-gene recurrence score in hormone receptor-positive, node-negative breast cancer","note":"Sparano JA, Gray RJ, Makower DF, et al. New England Journal of Medicine.","from":"paper-tailorx-nejm-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","note":"Litton JK, Rugo HS, Ettl J, et al. New England Journal of Medicine.","from":"paper-embraca-n-engl-j-med-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study","note":"Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Journal of Clinical Oncology.","from":"paper-hainsworth-j-clin-oncol","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features","note":"Hoadley KA, Yau C, Hinoue T, et al. (The Cancer Genome Atlas Network). Cell.","from":"paper-tcga-pancancer-atlas-cell-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"TGF-beta drives immune evasion in genetically reconstituted colon cancer metastasis","note":"Tauriello DVF, Palomo-Ponce S, Stork D, et al. Nature.","from":"paper-tauriello-tgfbeta-immune-evasion-colorectal-nature-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","note":"Mariathasan S, Turley SJ, Nickles D, et al. Nature.","from":"paper-mariathasan-nature","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"The biology and management of non-small cell lung cancer","note":"Herbst RS, Morgensztern D, Boshoff C. Nature.","from":"paper-herbst-nature","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"The long tail of oncogenic drivers in prostate cancer","note":"Armenia J, Wankowicz SAM, Liu D, et al. Nature Genetics.","from":"paper-armenia-long-tail-oncogenic-drivers-prostate-nat-genet-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"The molecular landscape of paediatric acute myeloid leukaemia (TARGET)","note":"Bolouri H, Farrar JE, Triche T, et al. Nature Medicine.","from":"paper-bolouri-paediatric-aml-genomics-nat-med-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment","note":"Bakhoum SF, Cantley LC. Cell.","from":"paper-bakhoum-cell","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug","note":"Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A. American Journal of Cancer Research.","from":"paper-juarez-ivermectin-repositioned-cancer-drug-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Thorsson 2018: the immune landscape of cancer across 10,000 tumours","note":"Thorsson V, Gibbs DL, Brown SD, et al. Immunity.","from":"paper-thorsson-immune-landscape-of-cancer-immunity-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Tolerance limits and methodologies for IMRT measurement-based verification QA: Recommendations of AAPM Task Group No. 218","note":"Miften M, Olch A, Mihailidis D, et al. Medical physics.","from":"paper-miften-med-phys","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","note":"Hernandez I, Prasad V, Gellad WF. JAMA Oncology.","from":"paper-hernandez-jama-oncol","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"TRAIN-2: neoadjuvant chemotherapy with or without anthracyclines alongside dual HER2 blockade","note":"van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. The Lancet Oncology.","from":"paper-train-2-lancet-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study","note":"Dix DB, Seibel NL, Chi YY, et al. Journal of Clinical Oncology.","from":"paper-dix-j-clin-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing","note":"Shimelis H, LaDuca H, Hu C, et al. JNCI: Journal of the National Cancer Institute.","from":"paper-shimelis-tnbc-risk-genes-jnci-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","note":"Denkert C, von Minckwitz G, Darb-Esfahani S, et al. The Lancet Oncology.","from":"paper-denkert-tils-neoadjuvant-pooled-lancet-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","note":"Bareche Y, Venet D, Ignatiadis M, et al. Annals of Oncology.","from":"paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clin...","note":"Kaufman HL, Russell JS, Hamid O, et al. Journal for ImmunoTherapy of Cancer.","from":"paper-javelin-merkel-200-j-immunother-cancer-2018-update","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors","note":"Lindeman NI, Cagle PT, Aisner DL, et al. Journal of Thoracic Oncology.","from":"paper-lindeman-lung-molecular-testing-guideline-jto-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases","note":"Gehl J, Sersa G, Matthiessen LW, et al. Acta oncologica.","from":"paper-gehl-acta-oncol","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Use of alternative medicine for cancer and its impact on survival","note":"Johnson SB, Park HS, Gross CP, Yu JB. JNCI: Journal of the National Cancer Institute.","from":"paper-johnson-alternative-medicine-jnci-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"USPSTF 2018: screening for prostate cancer, recommendation statement (grade C at 55 to 69, grade D at 70 and over)","note":"US Preventive Services Task Force, Grossman DC, Curry SJ, et al. JAMA.","from":"paper-uspstf-prostate-screening-jama-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"VE-BASKET: vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis","note":"Diamond EL, Subbiah V, Lockhart AC, et al. JAMA Oncology.","from":"paper-ve-basket-vemurafenib-erdheim-chester-lch-jama-oncol-2018","refs":[]},{"group":"paper","date":"2018","precision":"year","title":"Whole-genome and transcriptome sequencing of prostate cancer identifies new genetic alterations driving disease progression","note":"Ren S, Wei GH, Liu D, et al. European Urology.","from":"paper-ren-chinese-prostate-whole-genome-eur-urol-2018","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"[18F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer","note":"American Journal of Nuclear Medicine and Molecular Imaging","from":"robert-mach","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"10-year report on the European Paediatric Regulation and its impact on new drugs for children's cancers","note":"The Lancet Oncology","from":"gilles-vassal","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS","note":"Blood Advances","from":"jeffrey-miller","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferior...","note":"Lancet Oncology","from":"rachel-kerr","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"A causal mechanism for childhood acute lymphoblastic leukaemia","note":"Nature Reviews Cancer","from":"mel-greaves","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert...","note":"Modern Pathology","from":"cree-ian","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424","note":"British Journal of Cancer","from":"mark-middleton","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","note":"Annals of Oncology","from":"giampaolo-tortora","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer","note":"Cancer","from":"mark-middleton","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"A phase 2 study of the IDO inhibitor indoximod with chemotherapy in metastatic breast cancer","note":"Cancer Immunology Research","from":"hatem-soliman","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Abscopal effect of radiotherapy combined with immune checkpoint inhibitors","note":"Journal of Hematology & Oncology","from":"yu-jinming","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Access to cancer care in Colombia, a middle-income country with universal health coverage","note":"Journal of Cancer Policy","from":"carolina-wiesner","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries","note":"Eur J Cancer","from":"igor-stojkovski","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform pro...","note":"Annals of Oncology","from":"mahesh-parmar","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Rep...","note":"Journal of Clinical Oncology","from":"douglas-hawkins","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, mult...","note":"Lancet Oncology","from":"carien-creutzberg","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer (TAILORx)","note":"NEJM","from":"joseph-sparano","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (KEYNOTE-054)","note":"NEJM","from":"alexander-eggermont","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Advanced adenoid cystic carcinoma (ACC) is featured by SWI/SNF chromatin remodeling complex aberrations","note":"Journal of Cancer Research and Clinical Oncology","from":"beata-jagielska","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis: Results From a Scandinavian...","note":"Ann Surg","from":"bjorn-atle-bjornbeth","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer","note":"PLOS ONE","from":"brasil-silva-neto","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Apalutamide treatment and metastasis-free survival in prostate cancer (SPARTAN)","note":"NEJM","from":"matthew-smith","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer","note":"JAMA Oncology","from":"hidetoshi-hayashi","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer","note":"JAMA Oncology","from":"pilar-garrido","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel–Lindau Disease","note":"JAMA Oncology","from":"steven-k-libutti","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer (IMpassion130)","note":"NEJM","from":"peter-schmid","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomi...","note":"The Lancet Oncology","from":"paolo-veronesi","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis","note":"Science","from":"benjamin-kile","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","note":"Blood","from":"ralf-c-bargou","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia (BLAST)","note":"Blood","from":"nicola-gokbuget","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast","note":"JAMA Oncology","from":"r-r-w-j-van-der-hulst","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma (ECHELON-1)","note":"NEJM","from":"joseph-connors","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer (ALTA-1L)","note":"NEJM","from":"kim-dong-wan","refs":["ross-camidge"]},{"group":"person-paper","date":"2018","precision":"year","title":"Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibitio...","note":"The Lancet Oncology","from":"thomas-bachelot","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Burden of Cancer Among Syrian Refugees in Jordan","note":"Journal of Global Oncology","from":"asem-mansour","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Cancer immunotherapy using checkpoint blockade","note":"Science","from":"antoni-ribas","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Cancer of unknown primary: challenges and progress in clinical management","note":"Lancet Oncology","from":"linda-mileshkin","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Cancer vaccines on the move","note":"Nature Reviews Clinical Oncology","from":"karolina-palucka","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","note":"Lancet Oncol","from":"jean-philippe-spano","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","note":"Nature Medicine","from":"nirali-shah","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","note":"Nature Reviews Clinical Oncology","from":"sattva-neelapu","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study","note":"Journal of Clinical Oncology","from":"rahul-aggarwal","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Clinical and Pathological Characteristics of KEAP1 - and NFE2L2 -Mutated Non–Small Cell Lung Carcinoma (NSCLC)","note":"Clinical Cancer Research","from":"reinhard-buettner","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma","note":"Gynecologic Oncology","from":"annika-auranen","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain (CheckMate 204)","note":"NEJM","from":"hussein-tawbi","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Comprehensive characterization of cancer driver genes and mutations","note":"Cell","from":"li-ding","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Copy number signatures and mutational processes in ovarian carcinoma","note":"Nature Genetics","from":"james-brenton","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","note":"Leukemia","from":"katy-rezvani","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Cytokine release syndrome","note":"Journal for ImmunoTherapy of Cancer","from":"michael-von-bergwelt","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer (ROAR)","note":"JCO","from":"maria-cabanillas","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized Trial","note":"International Journal of Radiation Oncology*Biology*Physics","from":"renaud-de-crevoisier","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma (ALCYONE)","note":"NEJM","from":"maria-victoria-mateos","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, contro...","note":"Lancet Oncology","from":"noopur-raje","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test (CancerSEEK)","note":"Science","from":"nickolas-papadopoulos","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal","note":"Cell","from":"samra-turajlic","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"DNA methylation-based classification of central nervous system tumours","note":"Nature","from":"andreas-von-deimling","refs":["stefan-pfister"]},{"group":"person-paper","date":"2018","precision":"year","title":"Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia","note":"Science Translational Medicine","from":"ulrich-steidl","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","note":"NEJM","from":"courtney-dinardo","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Duration of adjuvant chemotherapy for stage III colon cancer (IDEA)","note":"NEJM","from":"aimery-de-gramont","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Editor's Choice – European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms","note":"European Journal of Vascular and Endovascular Surgery","from":"frank-vermassen","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Effect of a Strategy of a Supraglottic Airway Device vs Tracheal Intubation During Out-of-Hospital Cardiac Arrest on Functional Outcome: The AIRWAYS-2 Randomize...","note":"JAMA","from":"jonathan-benger","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Random...","note":"JAMA","from":"dawn-hershman","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer","note":"JAMA","from":"su-weiguo","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial","note":"JAMA","from":"li-jin-fuscc","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK...","note":"Haematologica","from":"antonio-cuneo","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","note":"New England Journal of Medicine","from":"alexander-drilon","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Elevated serum S‐100β in patients with septic shock is associated with delirium","note":"Acta Anaesthesiologica Scandinavica","from":"kristo-erikson","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS)","note":"Lancet Oncology","from":"paolo-ascierto","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Eradication of spontaneous malignancy by local immunotherapy","note":"Science Translational Medicine","from":"ronald-levy","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe","note":"Eur Respir J","from":"assia-konsoulova","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Factors influencing time to seeking medical advice and onset of treatment in women who are diagnosed with breast cancer in Serbia","note":"Psychooncology","from":"jasna-trifunovic","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Fanconi anaemia and cancer: an intricate relationship","note":"Nature Reviews Cancer","from":"d-wade-clapp","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Fatty pancreas: A possible risk factor for pancreatic cancer in animals and humans","note":"Cancer Science","from":"nakagama-hitoshi","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","note":"N Engl J Med","from":"pascal-hammel","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer (PRODIGE 24)","note":"NEJM","from":"thierry-conroy","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Functional genomic landscape of acute myeloid leukaemia","note":"Nature","from":"brian-druker","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, ph...","note":"Lancet Oncology","from":"wen-zhao-zhong","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","note":"New England Journal of Medicine","from":"louis-staudt","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","note":"Lancet Oncology","from":"ellen-copson","refs":["sunil-lakhani"]},{"group":"person-paper","date":"2018","precision":"year","title":"Global cancer control: responding to the growing burden, rising costs and inequalities in access","note":"ESMO Open","from":"ilbawi-andre","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers fr...","note":"Lancet","from":"ladislav-dusek","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","note":"Science","from":"laurence-zitvogel","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","note":"Science","from":"jennifer-wargo","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic...","note":"European Urology Oncology","from":"rahul-aggarwal","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"High dose rate brachytherapy as monotherapy for localised prostate cancer","note":"Radiother Oncol","from":"nikolaos-zamboglou","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation","note":"Lung Cancer","from":"li-weimin","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer (OVHIPEC-1)","note":"NEJM","from":"willemien-van-driel","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma","note":"New England Journal of Medicine","from":"christiane-pott","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma (AIM)","note":"NEJM","from":"constantine-tam","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL (Alliance A041202)","note":"NEJM","from":"jennifer-woyach","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Ictal and interictal electric source imaging in pre-surgical evaluation: a prospective study","note":"Eur J Neurol","from":"jannick-brennum","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Immune-related adverse events associated with immune checkpoint blockade","note":"NEJM","from":"michael-postow","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing’s sarcoma family of tumors (ESFT)","note":"Virchows Archiv","from":"antonio-llombart-bosch","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes","note":"Clinical Cancer Research","from":"bruno-sangro","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test","note":"Genetics in Medicine","from":"ronald-cohn","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN)","note":"Lancet Oncology","from":"ruth-ladenstein","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial","note":"Ann Surg","from":"bjorn-atle-bjornbeth","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial (REFLECT)","note":"Lancet","from":"masatoshi-kudo","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","note":"New England Journal of Medicine","from":"jae-park","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD)","note":"Lancet","from":"angelita-habr-gama","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice","note":"Gastroenterology","from":"maike-sander","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Magnetic resonance guided radiotherapy: the MR-Linac","note":"Clinical Oncology","from":"uwe-oelfke","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","note":"New England Journal of Medicine","from":"giovanni-scambia","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer (SOLO-1)","note":"NEJM","from":"kathleen-moore","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"MANAFEST: a functional assay to detect and track mutation-associated neoantigen-specific T cells","note":"Cancer Immunology Research","from":"kellie-smith","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Melanoma","note":"Lancet","from":"dirk-schadendorf","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Minimally invasive versus abdominal radical hysterectomy for cervical cancer (LACC)","note":"NEJM","from":"pedro-ramirez","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","note":"New England Journal of Medicine","from":"caroline-moore","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis (PRECISION)","note":"NEJM","from":"mark-emberton","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level","note":"Nature Medicine","from":"ulrich-steidl","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"National cancer control plans: a global analysis","note":"The Lancet Oncology","from":"ilbawi-andre","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Natural Killer Cell IFNγ Secretion is Profoundly Suppressed Following Colorectal Cancer Surgery","note":"Annals of Surgical Oncology","from":"rebecca-auer","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma","note":"Thyroid","from":"maria-cabanillas","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-lab...","note":"The Lancet Oncology","from":"sabine-linn","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","note":"Nature Medicine","from":"jennifer-wargo","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Neoadjuvant PD-1 blockade in resectable lung cancer","note":"New England Journal of Medicine","from":"patrick-forde","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma (CheckMate 214)","note":"NEJM","from":"robert-motzer","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort","note":"Blood Cancer Journal","from":"pierre-vera","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial","note":"Journal of Clinical Oncology","from":"chaturvedi-pankaj","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Oncobox Bioinformatical Platform for Selecting Potentially Effective Combinations of Target Cancer Drugs Using High-Throughput Gene Expression Data","note":"Cancers (Basel)","from":"ivan-s-stilidi","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (FLAURA)","note":"NEJM","from":"jean-charles-soria","refs":["ahn-myung-ju","ohe-yuichiro"]},{"group":"person-paper","date":"2018","precision":"year","title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS)","note":"Lancet Oncology","from":"reinhard-dummer","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"PAGE4 and Conformational Switching: Insights from Molecular Dynamics Simulations and Implications for Prostate Cancer","note":"Journal of Molecular Biology","from":"govindan-rangarajan","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Palpable Breast Lump Triage by Minimally Trained Operators in Mexico Using Computer-Assisted Diagnosis and Low-Cost Ultrasound","note":"Journal of Global Oncology","from":"susan-love","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Parastomal Hernia Repair; Seldom Performed and Seldom Reported: Results From a Nationwide Survey","note":"Scandinavian Journal of Surgery","from":"pia-nasvall","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01)","note":"JCO","from":"andrea-necchi","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Perturbation-response genes reveal signaling footprints in cancer gene expression","note":"Nature Communications","from":"julio-saez-rodriguez","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non–Small-Cell Lung Cancer","note":"Journal of Clinical Oncology","from":"goto-koichi","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer","note":"Clinical Breast Cancer","from":"patrick-morris","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti–PD-1 Therapy","note":"Cancer Immunology Research","from":"tasuku-honjo","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs","note":"Oncotarget","from":"derrick-haslem","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trast...","note":"Breast Cancer Research and Treatment","from":"ohno-shinji","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-S...","note":"Lancet Oncology","from":"steven-clifford","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Pa...","note":"British Journal of Haematology","from":"nicolaas-schaap","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Radiotherapy of glioblastoma 15 years after the landmark Stupp’s trial: more controversies than standards?","note":"Radiology and Oncology","from":"tomas-kazda","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Randomized Phase III Study of Cisplatin With Pemetrexed and Cisplatin With Vinorelbine for Completely Resected Nonsquamous Non–Small-Cell Lung Cancer: The JIPAN...","note":"Clinical Lung Cancer","from":"nobuyuki-yamamoto","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis","note":"JNCI: Journal of the National Cancer Institute","from":"carla-van-gils","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage","note":"Science","from":"owen-witte","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Rhabdomyosarcoma, Ewing Sarcoma, and Other Round Cell Sarcomas","note":"Journal of Clinical Oncology","from":"uta-dirksen","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","note":"Lancet Oncology","from":"debu-tripathy","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma","note":"New England Journal of Medicine","from":"franck-morschhauser","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Role of prostanoids in gastrointestinal cancer","note":"Journal of Clinical Investigation","from":"raymond-dubois","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre...","note":"The Lancet Oncology","from":"mark-middleton","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Screening performance of digital breast tomosynthesis vs digital mammography in the Malmö Breast Tomosynthesis Screening Trial","note":"Lancet Oncology","from":"kristina-lang","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Short interactive workshops reduce variability in contouring treatment volumes for spine stereotactic body radiation therapy: Experience with the ESTRO FALCON p...","note":"Radiotherapy and Oncology","from":"matthias-guckenberger","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Simultaneous cancer and tumor microenvironment subtyping using confocal infrared microscopy for all-digital molecular histopathology","note":"Proceedings of the National Academy of Sciences","from":"rohit-bhargava","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","note":"Blood","from":"lim-soon-thye","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation","note":"Blood","from":"jeffrey-miller","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma (CARMENA)","note":"NEJM","from":"arnaud-mejean","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Synthetic lethal therapies for cancer: what's next after PARP inhibitors?","note":"Nature Reviews Clinical Oncology","from":"alan-ashworth","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer (SOFT/TEXT)","note":"NEJM","from":"prudence-francis","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"The microRNA-15a-PAI-2 axis in cholangiocarcinoma-associated fibroblasts promotes migration of cancer cells","note":"Molecular Cancer","from":"yongyut-sirivatanauksorn","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia (ELIANA)","note":"NEJM","from":"stephan-grupp","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Toward the potential cure of leukemias in the next decade","note":"Cancer","from":"emil-freireich","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal","note":"Cell","from":"samra-turajlic","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis","note":"Am J Physiol Gastrointest Liver Physiol","from":"rasmus-mogelvang","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline","note":"JCO","from":"hedy-kindler","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phas...","note":"Lancet Oncology","from":"doi-toshihiko","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Tumor immune evasion arises through loss of TNF sensitivity","note":"Science Immunology","from":"trapani-joseph","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Tunicamycin specifically aggravates ER stress and overcomes chemoresistance in multidrug-resistant gastric cancer cells by inhibiting N-glycosylation","note":"Journal of Experimental & Clinical Cancer Research","from":"fan-daiming","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilo...","note":"European Journal of Cancer","from":"mario-campone","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire","note":"Health and Quality of Life Outcomes","from":"sandra-nolte","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-neg...","note":"Annals of Oncology","from":"david-cameron","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia (MURANO)","note":"NEJM","from":"john-seymour","refs":[]},{"group":"person-paper","date":"2018","precision":"year","title":"YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma","note":"Cancer Immunology Research","from":"shin-sang-joon","refs":[]},{"group":"technology","date":"2018","precision":"year","title":"ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)","note":"First use in humans or first approval, as the technology record states it.","from":"ctdna-lymphoma-monitoring","refs":[]},{"group":"technology","date":"2018","precision":"year","title":"FAPI PET","note":"First use in humans or first approval, as the technology record states it.","from":"fapi-pet","refs":[]},{"group":"technology","date":"2018","precision":"year","title":"FLASH research accelerators (Oriatron, Mobetron FLASH, ProBeam FLASH)","note":"First use in humans or first approval, as the technology record states it.","from":"flash-research-accelerators","refs":[]},{"group":"technology","date":"2018","precision":"year","title":"IDH inhibitors","note":"First use in humans or first approval, as the technology record states it.","from":"idh-inhibitors","refs":[]},{"group":"technology","date":"2018","precision":"year","title":"Lutetium-177 radioligand therapy","note":"First use in humans or first approval, as the technology record states it.","from":"lu177-radioligand-therapy","refs":[]},{"group":"technology","date":"2018","precision":"year","title":"Methylation classifier for brain tumours","note":"First use in humans or first approval, as the technology record states it.","from":"cns-tumour-methylation-classifier","refs":[]},{"group":"technology","date":"2018","precision":"year","title":"Peptide receptor radionuclide therapy (PRRT)","note":"First use in humans or first approval, as the technology record states it.","from":"prrt","refs":[]},{"group":"technology","date":"2018","precision":"year","title":"RAD51 foci assay (functional HRD test)","note":"First use in humans or first approval, as the technology record states it.","from":"rad51-foci-assay","refs":[]},{"group":"technology","date":"2018","precision":"year","title":"Radioligand therapy (beta emitters)","note":"First use in humans or first approval, as the technology record states it.","from":"radioligand-therapy","refs":[]},{"group":"technology","date":"2018","precision":"year","title":"Robotic and navigational bronchoscopy","note":"First use in humans or first approval, as the technology record states it.","from":"robotic-bronchoscopy","refs":[]},{"group":"trial","date":"2018","precision":"year","title":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer reported","from":"nct02107703","refs":["breast-hr-positive","abemaciclib","fulvestrant"]},{"group":"trial","date":"2018","precision":"year","title":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer reported","from":"nct02152631","refs":["nsclc","sclc","abemaciclib","erlotinib"]},{"group":"trial","date":"2018","precision":"year","title":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer reported","note":"Median metastasis-free survival 40.5 months with apalutamide added to androgen deprivation against 16.2 months with placebo (hazard ratio 0.28, 95 percent confidence interval 0.23...","from":"nct01946204","refs":["prostate","prostate-nmcrpc","apalutamide"]},{"group":"trial","date":"2018","precision":"year","title":"A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (C...","from":"nct00718549","refs":["leukaemia","cladribine","cyclophosphamide","rituximab"]},{"group":"trial","date":"2018","precision":"year","title":"ALTA-1L reported","note":"Median progression-free survival 24.0 vs 11.1 months (hazard ratio 0.48, blinded independent review, final analysis).","from":"alta-1l","refs":["nsclc","alk-positive-nsclc","brigatinib","crizotinib"]},{"group":"trial","date":"2018","precision":"year","title":"ALTER 0303 reported","note":"OS 9.6 vs 6.3 months, HR 0.68.","from":"alter-0303","refs":["nsclc","anlotinib"]},{"group":"trial","date":"2018","precision":"year","title":"ASPREE (ASPirin in Reducing Events in the Elderly) reported","note":"All-cause mortality HR 1.14; cancer mortality HR 1.31; no cancer prevention.","from":"aspree","refs":["aspirin"]},{"group":"trial","date":"2018","precision":"year","title":"BrighTNess reported","note":"Carboplatin added to neoadjuvant paclitaxel raised the pathological complete response rate and improved event-free survival in triple-negative breast cancer; veliparib added nothin...","from":"brightness","refs":["tnbc-early","tnbc","carboplatin","paclitaxel"]},{"group":"trial","date":"2018","precision":"year","title":"CARMENA reported","note":"Sunitinib alone was non-inferior to cytoreductive nephrectomy plus sunitinib for overall survival in intermediate- and poor-risk metastatic clear cell renal cell carcinoma.","from":"carmena","refs":["clear-cell-rcc","rcc","sunitinib"]},{"group":"trial","date":"2018","precision":"year","title":"CELESTIAL reported","note":"OS 10.2 vs 8.0 months, HR 0.76.","from":"celestial","refs":["hcc","hcc-advanced","cabozantinib"]},{"group":"trial","date":"2018","precision":"year","title":"CheckMate 142 reported","note":"dMMR nivolumab plus ipilimumab cohort: objective response 55 percent, twelve-month overall survival 85 percent. MSS cohort with cobimetinib: objective response 3 percent.","from":"checkmate-142","refs":["colorectal","msi-high-colorectal","nivolumab","ipilimumab"]},{"group":"trial","date":"2018","precision":"year","title":"CheckMate 204 reported","note":"Intracranial clinical benefit 57% and complete response 26% in the asymptomatic cohort.","from":"checkmate-204","refs":["advanced-melanoma","secondary-brain-tumours","melanoma","nivolumab"]},{"group":"trial","date":"2018","precision":"year","title":"CheckMate 214 reported","note":"8-year OS HR 0.72 (ITT), 0.69 (intermediate/poor risk).","from":"checkmate-214","refs":["rcc","clear-cell-rcc","nivolumab","ipilimumab"]},{"group":"trial","date":"2018","precision":"year","title":"COG AREN0532 reported","note":"Nephrectomy alone was adequate for very low-risk favourable-histology Wilms tumour, and intensified therapy improved outcomes for tumours with 1p and 16q loss of heterozygosity.","from":"aren0532","refs":["wilms-tumor","childhood-cancers","vincristine","dactinomycin"]},{"group":"trial","date":"2018","precision":"year","title":"COG AREN0533 reported","note":"Overall 4-year EFS 85.4% and OS 95.6% (vs 72.5% and 84.0% in NWTS-5); 4-year EFS 90.2% for LOH 1p/16q stage III-IV with augmented therapy.","from":"aren0533","refs":["wilms-tumor","vincristine","dactinomycin","doxorubicin"]},{"group":"trial","date":"2018","precision":"year","title":"COLUMBUS reported","note":"PFS 14.9 vs 7.3 months (HR 0.54); median OS 33.6 months.","from":"columbus","refs":["melanoma","braf-v600-melanoma","advanced-melanoma","encorafenib"]},{"group":"trial","date":"2018","precision":"year","title":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia reported","from":"nct00557193","refs":["all-leukemia","leukaemia","asparaginase","cyclophosphamide"]},{"group":"trial","date":"2018","precision":"year","title":"CPX-351 Study 301 reported","note":"OS 9.56 vs 5.95 months, HR 0.69; 5-year OS 18% vs 8%.","from":"cpx-351-301","refs":["aml","aml-secondary","cpx-351","cytarabine-7-3"]},{"group":"trial","date":"2018","precision":"year","title":"ECHELON-2 reported","note":"A+CHP improved progression-free and overall survival over CHOP in CD30-positive peripheral T-cell lymphoma; approved in November 2018.","from":"echelon-2","refs":["peripheral-t-cell-lymphoma","non-hodgkin-lymphoma","brentuximab-vedotin","cyclophosphamide"]},{"group":"trial","date":"2018","precision":"year","title":"ELIANA reported","note":"ORR 81%; 12-month OS 76%; 5-year OS 55%.","from":"eliana","refs":["all-leukemia","all-paediatric-relapsed","tisagenlecleucel"]},{"group":"trial","date":"2018","precision":"year","title":"EMBRACA reported","note":"PFS 8.6 vs 5.6 months, HR 0.54; OS HR 0.85, not significant.","from":"embraca","refs":["tnbc","breast-hr-positive","tnbc-metastatic","hr-positive-metastatic-post-cdk46"]},{"group":"trial","date":"2018","precision":"year","title":"EMPOWER-CSCC-1 reported","note":"Objective response 47% in the metastatic group; 46% in the pooled analysis of 193 patients with 16% complete responses.","from":"empower-cscc-1","refs":["advanced-cutaneous-scc","cutaneous-scc","skin-cancer","cemiplimab"]},{"group":"trial","date":"2018","precision":"year","title":"EsPhALL (EsPhALL2004 and EsPhALL2010) reported","note":"Imatinib with BFM chemotherapy gave four-year disease-free survival of 72.9 percent against 61.7 percent without imatinib in good-risk children (not significant); continuous imatin...","from":"esphall","refs":["all-paediatric-ph-positive","all-leukemia","leukaemia","imatinib"]},{"group":"trial","date":"2018","precision":"year","title":"FLAURA reported","note":"Median progression-free survival 18.9 vs 10.2 months (hazard ratio 0.46); median overall survival 38.6 vs 31.8 months (hazard ratio 0.80).","from":"flaura","refs":["nsclc","egfr-mutant-nsclc","osimertinib","gefitinib"]},{"group":"trial","date":"2018","precision":"year","title":"FRESCO reported","note":"Median overall survival 9.3 against 6.6 months (hazard ratio 0.65).","from":"fresco","refs":["colorectal","fruquintinib"]},{"group":"trial","date":"2018","precision":"year","title":"GRAALL-2005 reported","note":"Hyperfractionated cyclophosphamide did not improve remission, event-free or overall survival; five-year event-free survival was 52.2 percent overall and 55.7 percent under age 55 a...","from":"graall-2005","refs":["all-leukemia","leukaemia","cyclophosphamide"]},{"group":"trial","date":"2018","precision":"year","title":"HERBY reported","note":"Bevacizumab added to radiotherapy and temozolomide did not improve event-free survival in newly diagnosed paediatric high-grade glioma.","from":"herby","refs":["paediatric-high-grade-glioma","glioblastoma","bevacizumab","temozolomide"]},{"group":"trial","date":"2018","precision":"year","title":"IBCSG 23-01 reported","note":"Ten-year disease-free survival 76.8 percent without axillary clearance against 74.9 percent with it (hazard ratio 0.85); lymphoedema 4 against 13 percent.","from":"ibcsg-23-01","refs":["breast-cancer","breast-hr-positive","breast-her2-positive","tnbc"]},{"group":"trial","date":"2018","precision":"year","title":"Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance reported","from":"nct00582166","refs":["non-hodgkin-lymphoma","ibritumomab-tiuxetan","rituximab"]},{"group":"trial","date":"2018","precision":"year","title":"IDEA collaboration reported","note":"Three months non-inferior to six for CAPOX and for low-risk (T1-3 N1) disease; six months better for T4 or N2.","from":"idea-collaboration","refs":["colorectal","colon-cancer","folfox","capox"]},{"group":"trial","date":"2018","precision":"year","title":"IMpassion130 reported","note":"PFS HR 0.62 in PD-L1+; approval withdrawn 2021 (US).","from":"impassion130","refs":["tnbc","tnbc-metastatic","atezolizumab","paclitaxel"]},{"group":"trial","date":"2018","precision":"year","title":"IMpower133 reported","note":"OS 12.3 vs 10.3 months, HR 0.70.","from":"impower133","refs":["sclc","extensive-stage-sclc","atezolizumab","platinum-etoposide"]},{"group":"trial","date":"2018","precision":"year","title":"IMpower150 reported","note":"Median progression-free survival 8.3 against 6.8 months (hazard ratio 0.62) and significantly longer overall survival for atezolizumab with bevacizumab and chemotherapy over bevaci...","from":"impower150","refs":["lung-adenocarcinoma","nsclc","egfr-mutant-nsclc","atezolizumab"]},{"group":"trial","date":"2018","precision":"year","title":"International Watch & Wait Database reported","note":"Two-year local regrowth 25.2 percent, 97 percent of it in the bowel wall; five-year overall survival 85 percent, disease-specific survival 94 percent.","from":"iwwd","refs":["colorectal","rectal-cancer"]},{"group":"trial","date":"2018","precision":"year","title":"KATHERINE reported","note":"iDFS HR 0.50; OS HR 0.66.","from":"katherine","refs":["breast-her2-positive","her2-positive-early-breast-cancer","trastuzumab-emtansine","trastuzumab"]},{"group":"trial","date":"2018","precision":"year","title":"KEYNOTE-407 reported","note":"Pembrolizumab plus carboplatin and a taxane improved overall and progression-free survival over chemotherapy alone across PD-L1 levels; approved in October 2018.","from":"keynote-407","refs":["pdl1-high-nsclc","nsclc","lung-cancer","pembrolizumab"]},{"group":"trial","date":"2018","precision":"year","title":"KRISTINE reported","note":"Pathological complete response 44.4% (T-DM1 + pertuzumab) vs 55.7% (TCHP); more locoregional progression before surgery with T-DM1.","from":"kristine","refs":["breast-her2-positive","her2-positive-early-breast-cancer","trastuzumab-emtansine","pertuzumab"]},{"group":"trial","date":"2018","precision":"year","title":"LACC (Laparoscopic Approach to Cervical Cancer) reported","note":"4.5-year DFS 86.0% vs 96.5%; death HR 6.00 with MIS.","from":"lacc","refs":["cervical","early-cervical-cancer"]},{"group":"trial","date":"2018","precision":"year","title":"Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients reported","from":"nct00383708","refs":["pituitary-tumours","octreotide-lanreotide","pegvisomant"]},{"group":"trial","date":"2018","precision":"year","title":"Mastectomy Reconstruction Outcomes Consortium (MROC) reported","note":"At two years, autologous reconstruction gave higher satisfaction with breasts (7.94 points on the BREAST-Q), psychosocial and sexual wellbeing than implants, but roughly double the...","from":"mroc","refs":["breast-cancer","breast-hr-positive","breast-her2-positive","tnbc"]},{"group":"trial","date":"2018","precision":"year","title":"MAVORIC reported","note":"Mogamulizumab improved progression-free survival over vorinostat in previously treated mycosis fungoides and Sezary syndrome; approved in August 2018.","from":"mavoric","refs":["cutaneous-t-cell-lymphoma","peripheral-t-cell-lymphoma","mogamulizumab","vorinostat"]},{"group":"trial","date":"2018","precision":"year","title":"Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia reported","from":"nct01829711","refs":["leukaemia","moxetumomab-pasudotox"]},{"group":"trial","date":"2018","precision":"year","title":"MURANO reported","note":"Venetoclax plus rituximab greatly lengthened progression-free survival compared with bendamustine-rituximab, with high rates of undetectable minimal residual disease; approved in J...","from":"murano","refs":["cll-relapsed","cll","venetoclax","rituximab"]},{"group":"trial","date":"2018","precision":"year","title":"MyPathway reported","note":"Response in 23 percent of the first 230 patients; trastuzumab plus pertuzumab gave a 32 percent response rate in HER2-amplified colorectal cancer, now a guideline option; atezolizu...","from":"mypathway","refs":["colorectal","rare-cancers","gallbladder","cholangiocarcinoma"]},{"group":"trial","date":"2018","precision":"year","title":"NAVIGATE reported","note":"ORR 75% by independent review in the first 55 pooled patients across 17 tumour types.","from":"navigate","refs":["metastatic-cancer","ntrk-fusion-nsclc","larotrectinib"]},{"group":"trial","date":"2018","precision":"year","title":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy reported","from":"nct01874353","refs":["ovarian","platinum-sensitive-ovarian-cancer","olaparib"]},{"group":"trial","date":"2018","precision":"year","title":"OVHIPEC-1 reported","note":"OS 45.7 vs 33.9 months (HR 0.67).","from":"ovhipec-1","refs":["ovarian"]},{"group":"trial","date":"2018","precision":"year","title":"Photodynamic therapy against imiquimod against fluorouracil for superficial basal cell carcinoma reported","note":"Tumour-free survival at five years 80.5 per cent with imiquimod, 70.0 per cent with fluorouracil and 62.7 per cent with methyl aminolevulinate photodynamic therapy; imiquimod beat...","from":"mal-pdt-imiquimod-fluorouracil-superficial-bcc","refs":["basal-cell-carcinoma","skin-cancer","imiquimod","fluorouracil"]},{"group":"trial","date":"2018","precision":"year","title":"PORTEC-3 reported","note":"5-year OS 81.4% vs 76.1% (HR 0.70); benefit concentrated in p53-abnormal disease.","from":"portec-3","refs":["endometrial","endometrial-p53-abnormal","endometrial-pole-ultramutated","endometrial-nsmp"]},{"group":"trial","date":"2018","precision":"year","title":"PRECISION reported","note":"Clinically significant cancer 38% vs 26%.","from":"precision-mri","refs":["prostate","prostate-low-risk"]},{"group":"trial","date":"2018","precision":"year","title":"PRODIGE 24 / CCTG PA6 reported","note":"OS 54.4 vs 35.0 months, HR 0.64.","from":"prodige-24","refs":["pancreatic","resectable-pdac","folfirinox"]},{"group":"trial","date":"2018","precision":"year","title":"PROSPER reported","note":"Enzalutamide lengthened metastasis-free survival and, with longer follow-up, overall survival compared with placebo; approved in July 2018.","from":"prosper","refs":["prostate-nmcrpc","prostate","enzalutamide"]},{"group":"trial","date":"2018","precision":"year","title":"REFLECT reported","note":"OS 13.6 vs 12.3 months, non-inferior (HR 0.92).","from":"reflect","refs":["hcc","hcc-advanced","lenvatinib","sorafenib"]},{"group":"trial","date":"2018","precision":"year","title":"RELEVANCE reported","note":"Complete response at 120 weeks 48 percent with rituximab-lenalidomide against 53 percent with rituximab-chemotherapy (p 0.13) and median progression-free survival 120.2 against 123...","from":"relevance","refs":["follicular-lymphoma","non-hodgkin-lymphoma","lenalidomide","rituximab"]},{"group":"trial","date":"2018","precision":"year","title":"ROAR (anaplastic thyroid cancer cohort) reported","note":"ORR 56%; median OS 15 months.","from":"roar-atc","refs":["thyroid","dabrafenib-trametinib"]},{"group":"trial","date":"2018","precision":"year","title":"SCOT reported","note":"Three-year disease-free survival 76.7 percent with three months against 77.1 percent with six (hazard ratio 1.006, 0.909 to 1.114, non-inferiority p = 0.012), with grade 2 or worse...","from":"scot","refs":["colorectal","colon-cancer","capox","folfox"]},{"group":"trial","date":"2018","precision":"year","title":"SOLAR-1 reported","note":"PFS 11.0 vs 5.7 months, HR 0.65 (PIK3CA-mutant).","from":"solar-1","refs":["breast-hr-positive","hr-positive-metastatic-post-cdk46","alpelisib"]},{"group":"trial","date":"2018","precision":"year","title":"SOLO-1 reported","note":"PFS HR 0.30; 7-year OS 67.0% vs 46.5% (HR 0.55).","from":"solo-1","refs":["ovarian","high-grade-serous-ovarian-cancer","platinum-sensitive-ovarian-cancer","olaparib"]},{"group":"trial","date":"2018","precision":"year","title":"SPCG-4 (Scandinavian Prostate Cancer Group Study 4) reported","note":"Prostate cancer deaths 71 of 347 with surgery against 110 of 348 with watchful waiting (relative risk 0.55, 95 percent confidence interval 0.41 to 0.74); number needed to treat 8.4...","from":"spcg-4","refs":["prostate","prostate-low-risk","prostate-intermediate-risk","prostate-high-risk"]},{"group":"trial","date":"2018","precision":"year","title":"STOMP reported","note":"Median androgen deprivation-free survival 21 months with metastasis-directed therapy against 13 months with surveillance (hazard ratio 0.60, 80 percent confidence interval 0.40 to...","from":"stomp-oligorecurrence","refs":["prostate","prostate-bcr","prostate-mhspc"]},{"group":"trial","date":"2018","precision":"year","title":"TAILORx reported","note":"9-year iDFS 83.3% vs 84.3%; non-inferior.","from":"tailorx","refs":["breast-hr-positive","hr-positive-early-high-risk","oncotype-dx"]},{"group":"trial","date":"2018","precision":"year","title":"TNT (Triple Negative Trial) reported","note":"No superiority of carboplatin over docetaxel in unselected triple-negative disease; higher response to carboplatin in the germline BRCA1/2 subgroup (Nature Medicine 2018).","from":"tnt","refs":["tnbc","tnbc-metastatic","carboplatin","docetaxel"]},{"group":"trial","date":"2018","precision":"year","title":"TRAIN-2 reported","note":"Pathological complete response 67% without anthracycline vs 68% with; 3-year event-free survival 93.5% vs 92.7%.","from":"train-2","refs":["breast-her2-positive","her2-positive-early-breast-cancer","carboplatin","paclitaxel"]},{"group":"trial","date":"2018","precision":"year","title":"TROG 05.01 (chemotherapy added to radiotherapy after surgery for high-risk skin squamous cell carcinoma) reported","note":"Freedom from locoregional relapse at five years 87 per cent with chemoradiotherapy against 83 per cent with radiotherapy alone (hazard ratio 0.84, 95 per cent confidence interval 0...","from":"trog-05-01","refs":["cutaneous-scc","skin-cancer","carboplatin"]},{"group":"trial","date":"2018","precision":"year","title":"VITAL (VITamin D and OmegA-3 TriaL) reported","note":"Invasive cancer incidence HR 0.96 (vitamin D), 1.03 (omega-3); no benefit on primary endpoints.","from":"vital","refs":[]},{"group":"regulatory","date":"2018-01-12","precision":"day","title":"Olaparib: approval (US)","note":"gBRCA HER2-negative metastatic breast cancer (OlympiAD)","from":"olaparib","refs":[]},{"group":"regulatory","date":"2018-01-26","precision":"day","title":"Lutetium-177 dotatate: approval (US)","note":"SSTR+ gastroenteropancreatic NETs (NETTER-1)","from":"lutathera","refs":[]},{"group":"guideline","date":"2018-02","precision":"month","title":"NCCN 2018 update for Prostate cancer","note":"1 row added. Anchored to FDA approval of abiraterone for high-risk metastatic hormone-sensitive disease, February 2018 (LATITUDE, STAMPEDE).","from":"prostate","refs":["abiraterone","latitude","stampede","chaarted"]},{"group":"regulatory","date":"2018-02-16","precision":"day","title":"Durvalumab: approval (US)","note":"Unresectable stage III NSCLC after chemoradiation (PACIFIC)","from":"durvalumab","refs":[]},{"group":"regulatory","date":"2018-02-26","precision":"day","title":"Abemaciclib: approval (US)","note":"With aromatase inhibitor first line (MONARCH 3)","from":"abemaciclib","refs":[]},{"group":"regulatory","date":"2018-03","precision":"month","title":"Enfortumab vedotin: designation (US)","note":"Breakthrough Therapy designation","from":"enfortumab-vedotin","refs":[]},{"group":"regulatory","date":"2018-03-20","precision":"day","title":"Brentuximab vedotin: approval (US)","note":"First-line stage III/IV Hodgkin lymphoma with AVD (ECHELON-1)","from":"brentuximab-vedotin","refs":[]},{"group":"regulatory","date":"2018-03-29","precision":"day","title":"Blinatumomab: approval (US)","note":"MRD-positive B-ALL: first approval based on MRD","from":"blinatumomab","refs":[]},{"group":"guideline","date":"2018-04","precision":"month","title":"NCCN 2018 update for Melanoma","note":"1 row added. Anchored to FDA approval of adjuvant dabrafenib plus trametinib, April 2018 (COMBI-AD), following adjuvant nivolumab (December 2017).","from":"melanoma","refs":["dabrafenib-trametinib","combi-ad"]},{"group":"guideline","date":"2018-04","precision":"month","title":"NCCN 2018 update for Non-small-cell lung cancer","note":"1 row recategorised. Anchored to FDA approval of first-line osimertinib, April 2018 (FLAURA).","from":"nsclc","refs":["osimertinib","erlotinib","gefitinib","afatinib"]},{"group":"regulatory","date":"2018-04-06","precision":"day","title":"Rucaparib: approval (US)","note":"Recurrent ovarian maintenance (ARIEL3)","from":"rucaparib","refs":[]},{"group":"regulatory","date":"2018-04-16","precision":"day","title":"Ipilimumab: approval (US)","note":"With nivolumab in RCC","from":"ipilimumab","refs":[]},{"group":"regulatory","date":"2018-04-16","precision":"day","title":"Nivolumab: approval (US)","note":"With ipilimumab, intermediate/poor-risk RCC (CheckMate 214)","from":"nivolumab","refs":[]},{"group":"regulatory","date":"2018-04-18","precision":"day","title":"Osimertinib: approval (US)","note":"First-line EGFR-mutant NSCLC (FLAURA)","from":"osimertinib","refs":[]},{"group":"regulatory","date":"2018-05","precision":"month","title":"Galleri: designation (US)","note":"FDA Breakthrough Device designation","from":"galleri","refs":[]},{"group":"regulatory","date":"2018-06-03","precision":"day","title":"Oncotype DX: label change (US)","note":"TAILORx results define recurrence score ≤25 as chemotherapy-sparing","from":"oncotype-dx","refs":[]},{"group":"regulatory","date":"2018-06-08","precision":"day","title":"Venetoclax: approval (US)","note":"CLL/SLL with rituximab (MURANO)","from":"venetoclax","refs":[]},{"group":"regulatory","date":"2018-06-13","precision":"day","title":"Bevacizumab: approval (US)","note":"First-line ovarian cancer (GOG-0218)","from":"bevacizumab","refs":[]},{"group":"regulatory","date":"2018-06-27","precision":"day","title":"Binimetinib: approval (US)","note":"Encorafenib + binimetinib approved for BRAF V600 melanoma","from":"binimetinib","refs":[]},{"group":"regulatory","date":"2018-06-27","precision":"day","title":"Encorafenib: approval (US)","note":"BRAF V600 melanoma with binimetinib (COLUMBUS)","from":"encorafenib","refs":[]},{"group":"regulatory","date":"2018-07-18","precision":"day","title":"Ribociclib: approval (US)","note":"Pre/perimenopausal women and with fulvestrant (MONALEESA-7/-3)","from":"ribociclib","refs":[]},{"group":"regulatory","date":"2018-07-20","precision":"day","title":"Ivosidenib: approval (US)","note":"First IDH1 inhibitor","from":"ivosidenib","refs":[]},{"group":"regulatory","date":"2018-09-28","precision":"day","title":"Cemiplimab: approval (US)","note":"Advanced cutaneous squamous cell carcinoma: first systemic therapy approved for CSCC","from":"cemiplimab","refs":[]},{"group":"regulatory","date":"2018-10-16","precision":"day","title":"Talazoparib: approval (US)","note":"gBRCA HER2-negative locally advanced/metastatic breast cancer (EMBRACA)","from":"talazoparib","refs":[]},{"group":"regulatory","date":"2018-11-02","precision":"day","title":"Lorlatinib: approval (US)","note":"ALK+ NSCLC after prior ALK TKIs (accelerated)","from":"lorlatinib","refs":[]},{"group":"regulatory","date":"2018-11-16","precision":"day","title":"Brentuximab vedotin: approval (US)","note":"First-line CD30+ peripheral T-cell lymphoma with CHP (ECHELON-2)","from":"brentuximab-vedotin","refs":[]},{"group":"regulatory","date":"2018-11-21","precision":"day","title":"Venetoclax: approval (US)","note":"Newly diagnosed AML in unfit patients with azacitidine/decitabine/LDAC (accelerated)","from":"venetoclax","refs":[]},{"group":"regulatory","date":"2018-11-28","precision":"day","title":"Gilteritinib: approval (US)","note":"ADMIRAL interim; full OS data 2019","from":"gilteritinib","refs":[]},{"group":"regulatory","date":"2018-12-19","precision":"day","title":"Olaparib: approval (US)","note":"First-line maintenance in BRCA-mutated ovarian cancer (SOLO-1)","from":"olaparib","refs":[]}]},"route":"/years/2018/","neighbours":{"year":[{"id":"2017","kind":"year","name":"2017 in oncology","route":"/years/2017/"},{"id":"2019","kind":"year","name":"2019 in oncology","route":"/years/2019/"}]}}